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In the forensic science community, there is an immense need for tools to help assist 
investigations where conventional DNA profiling methods have been non-informative. 
Forensic DNA Phenotyping (FDP) aims to bridge that gap and aid investigations by 
providing physical appearance information when other investigative methods have been 
exhausted. To create a “biological eye witness”, it becomes necessary to constantly 
improve these methods in order to develop a complete and accurate image of the 
individual who left the sample.  
To add to our previous prediction systems IrisPlex and HIrisPlex, we have developed 
the HIrisPlex-S system for the all-in-one combined prediction of eye, hair, and skin color 
from DNA. The skin color prediction model uses 36 variants that were recently proposed 
for the accurate prediction of categorical skin color on a global scale, and the system is 
completed by the developmental validation of a 17-plex capillary electrophoresis (CE) 
genotyping assay that is run in conjunction with the HIrisPlex assay to generate these 
genotypes. The predicted skin color output includes Very Pale, Pale, Intermediate, Dark 
and Dark-to-Black categories in addition to categorical eye (Blue, Intermediate, and 
Brown) and hair (Black, Brown, Blond, and Red) color predictions. We demonstrate that 
the HIrisPlex-S assay performs in full agreement with guidelines from the Scientific 
Working Group on DNA Analysis Methods (SWGDAM), achieving high sensitivity 
levels with a minimum 63pg DNA input.  
In addition to adding skin color to complete the pigmentation prediction system 
termed HIrisPlex-S, we successfully designed a Massively Parallel Sequencing (MPS) 
assay to complement the system and bring Next Generation Sequencing (NGS) to the 
forefront of forensic DNA analyses methods. Using Illumina’s MiSeq system enables the 
generation of HIrisPlex-S’s 41 variants using sequencing data that has the capacity to 
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better deconvolute mixtures and perform with even more sensitivity and accuracy. This 
transition opens the door for a plethora of new ways in which this physical appearance 
assay can grow as sequencing technology is not limited by variant number; therefore, in 
essence many more traits have the potential to be included in this one assay design. For 
now, the HIrisPlex-S design of 41 variants using MPS is being fully assessed according 
to SWGDAM validated guidelines; therefore, this design paves the way for Forensic 
DNA Phenotyping to be used in any forensic laboratory. This new and improved 
HIrisPlex-S system will have a profound impact on casework, missing persons cases, and 
anthropological cases, as it is relatively inexpensive to run, HIrisPlex-S is easy to use, 
developmentally validated and one of the largest systems freely available online for 
physical appearance prediction from DNA using the freely available online web tool 
found at https://hirisplex.erasmusmc.nl/.  
Lastly, moving forward in our aim to include additional traits for prediction from 
DNA, we contributed to a large-scale research collaboration to unearth variants 
associated with hair morphology. 1026 samples were successfully sequenced using an in-
house MPS design at 91 proposed hair morphological loci. From this reaction, we were 
able to contribute to the identification of significant correlations between the SNPs 
rs2219783, rs310642 and rs80293268 with categorical hair morphology: straight, wavy or 
curly. 
1 
      
CHAPTER 1. INTRODUCTION 
1.1 Purpose and Objectives 
A forensic DNA profile is what many prosecutors hinge their cases and possible 
convictions upon. The current standard for DNA profiling in crime laboratories in the 
United States is STRs, or Short Tandem Repeats. These are used to develop and compare 
unknown profiles obtained at a crime scene to known suspect profiles obtained by 
detectives from a suspect individual or through the use of a national database like CODIS, 
the Combined DNA Indexing System [1]. STRs are an excellent method of determining 
the perpetrator of the crime when a suspect is known and an unknown sample is retained. 
This standard, however, is extremely unhelpful when a sample has been obtained from 
the crime scene, but there are no suspects in the case, no “hits” in national databases like 
CODIS, or when the DNA is too badly degraded for an STR profile to even be obtained. 
This is where technologies like Forensic DNA Phenotyping, or FDP, are vital to the 
progression of forensic science.  FDP enables the prediction of an individual’s externally 
visible characteristics from a sample left at a crime scene, therefore acting as a 
“biological eyewitness” [2]. 
FDP bypasses the limitations of DNA databases and ancestry testing alone and 
looks at specific locations in the genome that are correlated either directly or indirectly 
for normal variation in physical appearance between individuals. Researchers have 
developed systems like HIrisPlex and Snipper 2.5, that, through the use of Single 
Nucleotide Polymorphism (SNP) Multiplexing, can predict head hair pigmentation, skin 
pigmentation, eye pigmentation, and many other possible traits, with the potential for 
additional traits to be added through continued research [2-5]. These types of assays use 
SNPs, which are single base changes that occur at a specific spot in the genome or 
INDELS which are insertions or deletions that occur in a specific region of the genome. 
Not only do these types of variants offer new leads, but they also allow profiles to be 
generated from DNA material as low as 60pg/µl, which is significantly less than the 
published ranges needed for a typical STR profile [2, 6].  
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In 2014 the HIrisPlex system, a Forensic DNA Phenotyping tool released by 
Walsh et al. [7], and its validation were published for public use. This system is a 
combination of a SNP- SNaPshot all-in-one multiplex assay and prediction model for two 
externally visible characteristics; eye and hair pigmentation. Six of the SNPs that were 
incorporated into HIrisPlex were from a previous interactive model, termed IrisPlex [7]. 
IrisPlex is an eye pigmentation prediction tool developed by the same research group 
which classifies an individual’s eye pigmentation as being either blue, brown, or 
intermediate purely based upon their DNA [7]. This assay is fully compatible with 
SWGDAM guidelines, who govern forensic assays and validations [7, 8]. A measurement 
of accuracy termed AUC (Area Under the Receiver Operating Curve) was used to 
illustrate how accurate a prediction model such as this performs, where 0.5 denotes the 
random toss of a coin and a value of 1 equals a perfect prediction.  The AUCs for eye 
pigmentation were 0.95 for Brown, 0.94 for Blue, and 0.74 for Intermediate [8]. The 
HIrisPlex system combines eye pigmentation prediction with hair pigmentation 
prediction for a total of 24 DNA variants. The hair pigmentation portion of the prediction 
includes the categories of black, blond, brown, and red. It also incorporates light or dark 
hair shade into the model. This all-in-one multiplex assay was fully developmentally 
validated per SWGDAM guidelines for use in any forensic laboratory, giving AUC 
values for this model’s hair pigmentation prediction were 0.93 for red, 0.85 for black, 
0.81 for blond, 0.75 for brown [2]. The HIrisPlex system has not only been tested on data 
sets to prove its versatility, but it has also been used in casework and ancient remains to 
prove its practicality. A trial was conducted on 26 ancient, degraded samples of teeth and 
bones that are between 1 and 800 years old (post mortem). 23 of these samples yielded 
full HIrisPlex profiles [9]. These examples illustrate the reliability and necessity of 
implementing such a system in especially difficult casework where investigators are 
potentially limited by the lack of possible leads to pursue.  
While FDP is incredibly valuable in casework, continued research is required, 
especially with regards the addition of new externally visible characteristics such as skin 
pigmentation and hair morphology, for example. In Capillary Electrophoresis (CE) SNP 
analysis, which is the current technology used for FDP, Taq polymerase orchestrates the 
synthesis of millions of copies of a template DNA strand while incorporating 
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fluorescently tagged dideoxyribonucleotide triphosphates. These florescent tags are 
identified by the genetic analyzer based upon their different wavelengths and therefore 
result in the fragment being read by the analyzer. The biggest drawback to designing 
these assays on the CE is that the chemistry of the SNaPshot technology used caps the 
number of SNPs in an assay at around 25-30 SNPs. This means that adding in SNPs for 
new traits would mean adding in extra runs, more time, and more materials, which is an 
immense drawback as a forensic tool where sample and time may be very limited. MPS, 
also known as Massively Parallel Sequencing, is a technology that is changing the face of 
genetic research and could solve this problem. This relatively new form of sequencing 
differs from the typical Sanger method and also whole genome sequencing in that it 
allows a much higher throughput of samples by choosing many pieces, called amplicons, 
of DNA to sequence and not the entire genome. Machines like Illumina’s Miseq and 
ThermoFisher’s Ion Torrent, allow multiple fragments of the genome to be sequenced 
simultaneously, therefore resulting in the cost being drastically lower than the previous 
methods of individually sequencing genomes [10] or Sangers singular fragments. The 
ability of this technique to produce results from hundreds to thousands of variants in a 
single run is an ideal tool for forensic researchers as it allows the capacity to expand the 
number of variants required in FDP (in addition to ancestry estimation) to assist law 
enforcement investigations.  
Based upon the current state of FDP, the goal of this research is three-fold. The 
first goal is to assist in completing the design and validation of the HIrisPlex-S system 
and its model. This system uses 41variants to predict not only an individual’s eye and 
hair pigmentation, but their skin pigmentation as well, on a 5-category scale ranging from 
very pale to dark-to-black. The second goal of this research is the design and execution of 
a custom MPS Assay that translates the CE based HIrisPlex-S system to the Illumina 
Miseq FGx allowing FDP to be taken to the next level via this new platform. The final 
goal of the research is the design and execution of a custom MPS assay on the Illumina 
Miseq FGx to assess 91 SNPs for their correlation with categorical hair morphology 
association i.e. straight, wavy and curly. 
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1.2 The Pigmentation Pathway, Including Skin and Eye Melanin Formation and 
Distribution 
Pigmentation is one of the key distinguishing features between humans especially 
when looking at eye, hair, and skin pigmentation. This pigmentation is formed through 
melanin, which originates from neural crest cells that arise during the embryonic 
development and follow a very specific pathway. Research stemming from animal model 
studies has given us a better understanding of this pathway. In humans, α-MSH stimulates 
Melanocortin-receptor 1 (MC1R) causing the activation of the cAMP pathway. MC1R is 
a single exon and mutations and insertions in this gene tend to be associated with red hair, 
light skin, and freckles. MC1R controls the downstream regulation of the cAMP pathway. 
Down regulation of this results in low TYR and therefore a higher production of 
pheomelanin [11]. However, if ASIP, an antagonist, binds to MC1R instead of α-MSH, it 
shifts the synthesis towards pheomelanin by reducing TYR. Without ASIP the process 
tends toward eumelanin which requires further enzymatic activity [10]. 
 MITF is then introduced into the pathway resulting in the expression of TYR, 
TYRP1 and DPC.  Tyrosinase catalyzes, and is the limiting reagent to, the oxidation of 
tyrosine to DOPAquinone [12]. Tyrosinase (TYR) is an enzyme that catalyzes steps one 
and two of melanogenesis and is required for both eumelanin and pheomelanin 
production. Up regulation of this enzyme (often due to a neutral pH, as opposed to an 
acidic pH which results in pheomelanin) results in the synthesis of eumelanin. 
Tyrosinase-related protein (TYRP1) follows and is required for eumelanin only [11]. Both 
types of melanin; eumelanin and pheomelanin, are derivatives of 3,4di-
hydroxyphenylalanine [11].   
 From this point in the pathway, the resultant melanin is based upon the presence 
or absence of Cysteine. Cysteintyldopa is produced  and stagnant until Cysteine is present 
for it to oxidate to [11]. This therefore initiates small molecule transport, ion transport, 
and pH regulation.  Oculocutaneous Albinism II (OCA2) encodes the p protein, which is 
involved in the transfer of small molecules to initiate melanogenesis. Solute carrier 
families (SLC) transport proteins SLC24A4 and SLC24A5 are sodium-calcium 
transporters that are potassium dependent, the latter being involved in the regulation of 
calcium within the melanosome. Two-pore segment channel 2 (TPCN2) participates in a 
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similar function as well [11].  In the end, eumelanin is responsible for darker 
pigmentations such as brown-black pigment where as its counterpart, pheomelanin, is 
responsible for the lighter pigmentations such as the red-yellow pigment. The difference 
in the amounts (ratio) of pheomelanin to eumelanin then portrays the visible 
differentiations in eye, hair, and skin pigmentation [11].  
 
Figure 1 The biochemical pathway and synthesis of pheomelanin and eumelanin 
 
The process by which melanocytes develop is a four-step process. In the 
beginning, vacuoles arising from the endoplasmic reticulum and bud to form 
premelanosomes. The premelanosomes then take in enzymes such as TYR and structural 
proteins to begin melanin synthesis. The product of this step is melanosomes. At this 
stage eumelanosomes require more enzymes along with a fibrillar matrix over 
pheomelanosomes. At this point, only these melanosomes proceed to steps three and four 
of the process. These eumelanosomes import TYRP1 and DCT to continue. Melanosomes 
then become transferred to the keratinocytes near already formed melanocytes. This 
mode of transportation to the keratinocytes is not certain, but the leading hypothesis 
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involves the release of these melanosomes in which they are taken in by the keratinocytes 
by phagocytosis [11].  
For melanin formation in the skin, melanocytes in the epidermis reside in the 
basal layer along with keratinocytes. Melanosomes migrate from the melanocytes to the 
keratinocytes. The keratinocytes then rise to the upper layers of the skin to produce the 
visible skin pigmentation that is apparent to the naked eye [12]. The skin pigmentation of 
an individual depends on several key factors such as size, cellular distribution, number, 
and the type of melanosome that are present in the epidermis [11]. Figure 2 obtained from 
Yamaguchi et al depicts the development and distribution of melanosomes in human skin 
[13].  
 
 
Figure 2 Yamaguchi et al. depiction of the development and distribution of melanosomes 
in human skin. SC, stratum corneum; G, stratum granulosum; S, stratum spinosum; B, 
stratum basale; BM, basement membrane; D, dermis. Cell types: K, keratinocyte; M, 
melanocyte; F, fibroblast; shaded oval, melanin granule 
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Hair color is similar in development to skin color in many ways. The melanocytes 
are located in the proximal bulk of each hair bulb as well as the sebaceous gland.  The 
melanocytes transfer the melanosomes to keratinocytes similarly as in the skin, which 
then move to the shaft of the hair to produce visible pigmentation [12]. The life cycle of 
the melanocytes in the hair die at the end of the hair cycle, which only tends to last about 
3-8 years as opposed to epidermal melanocytes, which have a much longer life span. The 
melanogenisis of the hair only takes place during the anagen stage, which is the growing 
stage of the hair. This process is turned off in the catagen phase and completely absent in 
the telogen phase [12].  
Melanin formation in the eye differs in its formation from that found in hair. In 
eye pigmentation, blue and brown eyes have a similar number of melanocytes, but the 
visible pigmentation difference resides in the number of melanosomes that make up the 
melanin content of these melanocytes in the stroma. This lack of melanin in blue eyes 
allows for the penetration of light through the stroma, resulting in only a small amount 
being absorbed and the rest scattered [14]. This therefore gives the eye the appearance of 
blue, as melanin content increases we begin to see the hazel to intermediate eye color and 
proceeding to brown eyes.  
 
1.2.1 Some Evolutionary Theories of Pigmentation Lightening 
Melanin content is vital in the protection from radiation, especially UVB radiation, 
from the sun as well as necessary for Vitamin D absorption. It has been proven that both 
environmental factors like the sun and genetic factors can play a role on this externally 
visible characteristic’s pigmentation along with the distribution and quantity of melanin 
[15]. Evidence supports the idea that our ancestors originated in Africa about 150,000 
years ago [16]. Around 55-60,000 years ago, our ancestors began to migrate out of Africa. 
Through mitochondrial and Y-chromosomal analysis, they have been traced out of Africa 
and into the Eurasian continent. As they moved away from the equator their needs for 
protection from ultra-violate radiation and climate protection changed due to the need to 
absorb vitamin D amongst others [15]. Based upon this change we can see a variation in 
the skin pigmentation as latitude changed. 
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In addition to this theory, evidence in recent research especially by that of Norton 
et al. [16] has supported the idea of certain traits, especially eye, hair, and skin color may 
also be the product of convergent evolution over thousands of years. Genes such as s 
SLC24A5, MATP, and TYR have been identified in resulting in lighter pigmentations in 
individuals of European descent, but not of East Asian descent [17]. This supports the 
idea that while some genes such as OCA2 and ASIP may play a key role in overall global 
skin pigmentation distribution, there is also evidence to suggest lighter pigmentation 
arose independently in certain populations.  
Recently in 2017 Crawford et al. [17] published a study on African genomes that 
supported a hypothesis that challenges the idea of lightening as migration occurred from 
the equator. Their work with the genes MFSD12, DDB1, OCA2, and HERC2 supports the 
idea that the ancestral allele of these SNPs actual encodes for lighter skin pigmentation. 
This then follows the theory that darker pigmentation originated in the last 2 million 
years after our ancestors lost their protective hair covering leading to the exposure of 
their lighter skin. However, they also present evidence to support the idea that the darker 
pigmentation in South East Asian populations may indeed result from a common African 
ancestor whose migration route led them out of African and into East Asia. Ultimately, it 
may be possible that both factors of convergent evolution and natural selection are behind 
the pigmentation of the skin [18].  
1.3 Categorical Eye, Hair and Skin Pigmentation Associated Markers 
For this research, the previously developed HIrisPlex system is at the core of 
development for these additional assays. Therefore, it is vital to understand the SNPs that 
comprise HIrisPlex. In 2014, Walsh et al. published the HIrisPlex assay as well as its 
forensic validation. Each of the 24 SNPs included in this multiplex assay were selected 
because they provide a high correlation and prediction for eye and/or hair pigmentation 
of the individual at hand. This assay includes 11 different genes MC1R, HERC2, OCA2, 
SLC45A2, KITLG, EXOC2, TYR, SLC24A4, IRF4, ASIP, and TYRP1. 6 of these markers 
were established in the IrisPlex system [7, 8, 19].  The largest contributor to the 
prediction of eye pigmentation is rs12913832 in the HERC2 gene. This gene carries a 
substantial amount of weight as it has been proposed to be a causal marker for eye color 
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prediction [21] due to its regulation of OCA2, while also affects hair and skin 
pigmentation [19-21] to a lesser degree. The presence of an ‘A’ allele, Adenine, at this 
SNP enhances the expression of OCA2 while a ‘G’, Guanine, has been shown to 
downregulate its expression [22]. The increase in regulation, the ‘A’, results in an 
increase in melanin product, which results in darker eye pigmentation (brown). Mutations 
in OCA2 have been linked to ocular albinism, which results in the lack of pigmentation in 
the Iris, therefore indicating the inclusion of rs1800407 [17].  
Sturm et al. then identified by performing Genome Wide Association Study 
(GWAS) that TYRP also has a large effect on eye pigmentation followed by SLC45A2 
[23]. The three remaining SNPs of rs12896399 (SLC24A4), rs1393350 (TYR) and 
rs12203592 (IRF4) were then also identified and associated with eye pigmentation by 
Han et al. in 2008 on over 7,000 people from three studies, but also labeled as being 
associated with hair pigmentation and skin pigmentation [24]. These six SNPs mentioned 
above were confirmed as the six major genetic contributors for eye pigmentation by a 
systematic study by Liu et al. [19] as well.   
The MC1R variants of rs1805006, rs11547464, rs1805007, rs1805008, rs1805009, 
rs1805005, rs2228479, and rs885479 were associated with red hair and pale skin from a 
study containing family members and twins conducted by Sturm et al. [25]. In addition to 
these MC1R SNPs N29insA (rs312262906), Y152OCH (rs201326893), and rs1110400 
were added to a mini-sequencing protocol for a sequencing screen for the red hair 
phenotype and were found to be influential on this phenotype by Grimes et al. [26] in 
2001.  
Eiberg et al. [26] looked at a large Danish family to perform linkage analysis to 
fine-map the blue eye pigmentation locus. Variants such as rs12913832 and rs1129038 
were associated with blue and brown eye pigmentation, which was previously recognized 
in its location of intron 86 of HERC2 just upstream of OCA2 [27]. Rs683 (TYRP1), 
rs1042602 (TYR), was identified by Frudakis et al. to be an influencing factor in eye 
pigmentation [28] therefore explaining the addition of some of these SNPs to the 
HIrisPlex assay.  
In 2008 Han et al. [23] found in a study of over 10,000 individuals of European 
ancestry from the United States and Australia, that rs12896399 (SLC24A4), rs12821256 
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(KITLG), and rs12203592 (IRF4) had a strong association with hair pigmentation. 
Rs12203592 (IRF4) was also associated with eye and skin pigmentation along with skin 
tanning ability [24].  
Mengel-From et al. [30] found in a study of 33 candidate genes from a population 
of Danish and Scottish individuals, rs26722 (SLC45A2), rs7170852 (HERC2) rs916977 
(HERC2), rs1129038 (HERC2), rs11636232 (HERC2) and rs2238289 (HERC2), 
rs1470608 (OCA2) to be associated with darker hair pigmentation and rs10777129 
(KITLG) to be associated with lighter hair pigmentation [30]. Valenzuela et al. [19] also 
found three of these SNPS- rs16891982 (SLC45A2), rs1426654 (SLC24A5), and 
rs12913832 (HERC2) to be important to the total hair melanin content [19]. 
In 2011 Branicki et al. [28] published their thorough results of a hair color 
systematic study performed using Polish Europeans in which they assessed all known 
hair pigmentation markers and found that 13 genetic markers from 11 genes predicted 
hair pigmentation with an overall accuracy of 0.8 Area Under the receiver-operating 
Curve (AUC). Of these SNPs, in addition to the MC1R SNPs, they recommended the use 
of rs12913832 (HERC2) and rs1800414 (OCA2) for eye pigmentation. Rs12913832 
(HERC2) was also recommended for hair pigmentation in that it showed a dominant 
effect on darker hair pigmentation [29]. Black hair was most commonly associated with 
rs28777 (SLC45A2), rs12203592 (IRF4), and rs4959270 (EXOC2). SLC45A2 was 
associated with hair pigmentation melanin content on a whole as well. Rs2378249 
(ASIP/PIGU) was associated with red, dark blond, and red blond hair. Rs4778138 (OCA2) 
was found by this group to be highly associated with brown hair along with Rs1393350 
(TYR). Rs4904868 (SLC24A4) however was largely associated with blond and dark blond 
hair [29]. Thus, allowing the HIrisPlex hair and eye pigmentation prediction model to be 
complete. 
In addition, the same group in 2014, Pospiech et al. [29] substantiated and added 
to these findings by performing an analysis of 718 Polish sample, which yielded 38 
polymorphisms from 13 genes. Several of these SNPs, such as the previously mentioned 
rs312262906, rs11547464, rs885479, rs1805008, rs1805005, rs1805006, rs1802007, 
rs2228479, rs203132689, rs1110400, and rs1805009, all of which are part of MC1R, 
were found to be associated with red hair along with rs4911414 in ASIP [30]. 
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Rs12913832 (HERC2) was identified again as having an association with blue, brown 
and hazel eyes as well as blond hair. Rs12203592 (IRF4), rs16891982 (SLC45A2), and 
rs2402130 (SLC24A4) were also found to have a statistically significant effect on 
blond/red/brown/black hair pigmentation [30].  
Conversely, the approach taken to determine the genes and SNPS influencing skin 
pigmentation required a very different approach. Many of the genes identified relating to 
skin pigmentation were identified through positive selection. This was necessary because 
it is advisable to perform GWAS studies on single populations for skin color, to avoid 
population stratification where as in hair and eye color this was not a concern due to its 
variation being restricted to a singular population such as European and its immediate 
surrounding area. To further understand the genetic factors behind this trait and how they 
were found, in 2007, eight genes were identified to be associated with the melanin 
pathway by Lao et al. [15]. These genes included SLC45A2, OCA2, TYRP1, DCT, KITLG, 
EGFR, DRD2, and PPARD. The work from this group helped to support the idea that 
derived alleles correlate to lighter skin pigmentation while the ancestral alleles correlate 
to darker skin pigmentation. They found that rs3782974 (DCT), rs1800414 (OCA2), 
rs1448484 (OCA2), rs2762464 (TYRP1) and rs16891982 (SLC45A2) were all associated 
with skin pigmentation as well as a signature of positive selection [16].  
Simultaneously, in 2007, a novel GWAS was performed on a South Asian 
population by Stokowski et al. During this GWAS, this group discovered three genes 
SLC24A5, TYR, and SLC45A2. These were found to have highly significant associations 
with skin pigmentation in addition to the previous finding by Lao et al. [30]. They 
discovered that SNP rs1426654 (SLC24A5) does not change among European 
populations, but rather is solely related to individuals outside of Europe, such as the 
South Asians, whereas rs16891982 SLC45A2 and rs1042602 TYR displayed an increase 
in minor allele frequency with a decrease in latitude [31].  
Duffy et al. [31] in 2010 added to these findings on skin pigmentation by 
exhibiting that rs28777, rs35391, and rs16891982 in SLC45A2 illustrated a minor 
association with an increased risk of cutaneous malignant melanoma, but not any more so 
than the previously observed in the MC1R mutation [32]. For skin reflectance 
rs16891982, (SLC45A2), rs1426654 (SLC24A5), rs2434984 (ASIP) were found to be 
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influential by Valenzuela et al. [21], but only with 45% R2 value, therefore making the 
addition of more skin pigmentation prediction SNPs essential.  
Pospiech et al. [29] also found that certain MC1R mutations influenced skin 
pigmentation, along with TYR and SLC45A2, especially SNPs rs1042602 (TYR), 
rs1393350 (TYR), rs16891982 (SLC45A2) and rs28777 (SLC45A2). This association was 
followed shortly by rs4911414 (ASIP) and rs1800407 (OCA2) [30] .  
Jacobs et al. [32] took a novel approach to pigmentation research and digitally 
quantified skin pigmentation in 5,860 Dutch individuals from which they looked at 
14,185 SNPs from 281 candidate genes. Two new genes were identified as significant 
during this study- UGT1A and BNC2, that had not been previously tied to skin 
pigmentation. Previously, UGT1A has been shown to influence bilirubin and the levels of 
this in the blood. BNC2, specifically SNP rs10756819, was also shown to be significant. 
This gene was selected as a candidate gene because of its association to coat 
pigmentation in mice with a mutation resulting in a loss of brown pigment. Similarly this 
was seen in a disrupted stripe pattern in zebrafish when a mutation is present in this gene 
as well [33].  
In 2017 Crawford et al. [17] addressed an essential area of human pigmentation in 
which more information is needed. Crawford et al. looked at 1570 African genomes to 
identify variants that were associated with skin pigmentation to possibly gain more 
insight to the origins of human pigmentation. Their research indicated that SLC24A5 was 
introduced in to the East Asian population through migration routes out of Africa. Genes 
MFSD12, DDB1, TMEM138, OCA2, and HERC2 were found to be significant in relation 
to skin pigmentation [18]. Thus 29% of all pigmentation in Africans was identified to be 
in relation to these SNPs and possibly increasing the knowledge base as to the rise of 
lighter versus darker skin pigmentation [18].  
1.4 Categorical Skin Color Predictive Markers 
In terms of predicting skin color using these associated markers, Hart et al. [5] in 
2013 developed an 8-plex system, mentioned briefly above, which included rs12896399 
(SLC24A4), rs12913832 (HERC2), rs1545397 (OCA2), rs16891982 (SLC45A2), 
rs1426654 (SLC24A5), rs885479 (MC1R) and rs6119471 (ASIP), and rs12203592 (IRF4) 
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[5]. Six of these SNPs, rs12913832 (HERC2), rs1545397 (OCA2), rs16891982 
(SLC45A2), rs1426654 (SLC24A5), rs885479 (MC1R) and rs6119471 (ASIP), were used 
to designate skin pigmentation to be light, not dark, or not light. Based upon the 
European test set used, this assay’s prediction was seen as being 94% accurate therefore 
establishing one of the earlier skin pigmentation prediction tools [5] however their high 
level of inconclusive predictions were a cause for concern [34, 35]. 
Liu et al. [20] also performed a genome wide association study in 2015 shortly 
following the previously mentioned publications of prediction models on a total of 
17,262 European individuals, which replicated and furthered many of the findings 
previously mentioned [20]. They then followed this GWAS up with a functional study. 
This 2015 GWAS identified five regions of the genome that were believed to be 
associated with skin pigmentation. These areas include the genes SLC45A2, IRF4, OCA2, 
HERC2, MC1R, and ASIP. From this study, they could identify the top 9 influencing 
factors on skin pigmentation. These SNPs include: rs183671 (SLC45A2), rs12203592 
(IRF4), rs10756819 (BNC2), rs1393350 (TYR), rs17128291 (SLC24A4), rs12913832 
(HERC2), rs2924567 (SLC24A5), rs4268748 (MC1R), and rs6059655 (RALY/ASIP). 
Based upon their functional study using melanocyte cell lines, these individuals could 
determine that the expression of ASIP in the skin occurs in the dermis rather than the 
epidermis. It is possible that units in the dermis such as fibroblasts secrete ASIP, which 
then interacts with MC1R. This supports the idea that not only the epidermis, but also the 
dermis plays a role in pigmentation [36]. 
In 2014 Maronas et al. [3] published their own forensic skin pigmentation 
predictive tool. Using 285 samples from unrelated Europeans and non-Europeans, skin 
pigmentation associated SNPs were tested. These SNPs were identified using patterns of 
allele frequency along with literature reviews. A total of 59 SNPs were originally isolated 
and then narrowed down to sets of 10 and 6 SNPs [3]. The ten SNP set has SNPs that are 
present in 8 pigmentation genes. SNPs rs16891982 (SLC45A2) and rs1426654 (SLC24A5) 
were included in this assay based upon their predictive ability in the lighter skin colors. 
The SNP rs1426654 (SLC24A5) was noted as playing a large role in differentiating black 
and white to the rest. The effect of white versus the rest was also replicated in rs6119471 
(ASIP).  The final set of SNPs used for the reaction were rs10777129, rs13289, 
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rs1408799, rs1448484R, rs16891982, rs2402130, rs3829241, and rs6058017, in addition 
to those mentioned above [3].  
1.5 Hair Structure Formation 
Another aspect of this thesis involves fundamental research on the structure of 
human head hair.  Hair growth occurs in a cyclic pattern that tends to last anywhere from 
3 to 8 years [12]. The first phase of the cell cycle is the Anagen phase, which is a phase 
of growth for the hair follicle and the phase in which melanogenisis occurs. This is the 
longest phase of the cycle. The length of this phase varies based upon the location of the 
hair on the body [37]. This phase is followed by the Catagen phase in which separation of 
the follicle occurs and melanogenisis ends. The Telogen phase then follows and includes 
a phase of resting without any sign of melanin production. The final phase, the Exogen 
phase, then occurs in which the hair shaft is shed and then a new anagen phase is initiated. 
The length of each stage can vary based upon each hair and a pattern has been seen in 
aging in which the Anagen phase decreases and the Exogen phase increases with age [37].  
While pigmentation differences are the most noticeable hair-feature differences 
between individuals, the morphology of the hair is also a very distinguishing feature. In 
the determination of whether an individual has straight or curly hair, the shape of the hair 
shaft seems to be intrinsically programmed in the hair follicle. Curly hairs seems to have 
a club like shape at their base and this asymmetrical shape tends to extend upward along 
the inner root sheath creating the curly shape of the hair [38].  The shape of the follicle 
tends to dictate the morphology of the hair; therefore, a straight follicle means a straight 
hair and a clubbed follicle indicates a curly hair. In addition to this, a differentiation in 
thickness on one side versus the other of the outer root shaft also seems indicative of 
curly hair [37].   
15 
      
 
Figure 3 Photos A and C display uniform thickness of both sides of the outer root shaft of 
a straight hair versus B and D in a curly hair. 
1.6 Markers Associated with Categorical Hair Morphology 
With regards hair structure, a large study collaboration to identify markers 
associated with this trait was undertaken. A list of 91 potential markers was provided by 
collaborators, some previously published, others simply proposed. To generate accurate 
genotypes to assess these markers, it was necessary to design an MPS hair morphology 
assay on the Miseq sequencer. Some background on this list of markers is detailed below.  
Marcinska et al. [38] created a simple 5-SNP assay along with a 20 SNP 
prediction model from 50 SNPs for Androgenetic Alopecia. These models were based on 
SNPS from 305 males. These males were European and either over 50 years old and had 
not started balding or under 50 with significant baldness. The loss of hair makes some of 
these SNPs interesting as possible indicators of hair structure. While identifying these 
genes, the 5 SNP model was created using rs5919324 (upstream of AR), rs1998076, 
rs929626 (EBF1), rs12565727 (TARDBP), and rs756853 (HDAC9) [39]. Rs5919324, for 
example, a ‘T’ allele makes a male 2.1 times more likely to have male pattern baldness as 
opposed to the ‘C’ allele. Their extended model included SNPs rs1041668, rs5919324 
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(upstream of AR), rs6625163, rs6625150, rs962458, rs12007229, rs1998076, rs2180439, 
rs913063, rs1160312, rs6113491, rs756853 (HDAC9), rs6461387, rs6945541, 
rs12565727 (TARDBP), rs7349332 (WNT10A), rs4679955 (SUCNR1/MBNL1), rs929626 
(EBF1), rs9668810, and rs10502861 [39].  
Li et al. [39], in 2012, performed a genome wide association study on 12,806 
individuals who were of European ancestry who suffer from early onset Androgenetic 
Alopecia as well allowing the indication of several additional SNPs. This GWAS allowed 
the identification of the SNPs rs12565727 (TARDBP), rs9287638 (HDAC4), rs2073963 
(HDAC9), rs6945541 (AUTS2), rs12373124, rs10502861 (SETBP1), rs6047844 (PAX1, 
FOXA2), and rs2497938 (AR) [40]. 
Buket et al. [40] just recently released a study in December of 2016 looking to 
identify the causal variants behind “un-combable hair syndrome”. This disorder makes 
the individual’s blond, dry, wiry hair truly impossible to comb. This study revealed a 
triangular shaped cross-section of the hair as opposed to the typical round shape observed. 
This study could identify that the genes PADI3, TGM3, and TCHH. Upon knocking out 
PADI3 in mice, this group confirmed that this enzyme is essential to prevent this disorder. 
In mice, its knockout causes alterations in whiskers and hair coat of the animal. Their 
coat became wavy and whiskers were irregular and twisted, solidifying the functional 
genetics behind these variants [41].  
The VDR gene has been proven to be essential in hair follicle integrity, not 
necessarily hair morphogenesis as previously hypothesized. It has been proven that in 
mice with this gene knocked out develop alopecia.  This gene’s interaction with DNA is 
essential for the hair cycle to continue after embryonic development and therefore makes 
the SNPs vital to assess [42]. 
LGR4 in knockout mice was shown to have reduced amounts of EDAR, LEF1, 
and SHH which is essential for mouse hair follicle development. This suggests that if 
there is a deficiency in LGR4 there is a reduction of signal to keratinocytes for hair 
morphogenesis and therefore may play a role in hair morphology in humans [43].  
1649 individuals from 837 families were used by Medland et al. [43] to identify 
SNPs that indicated that the TCHH plays a significant role in determining hair structure. 
Four key SNPs were identified in this investigation rs17646946, rs11803731, rs4845418, 
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and rs12130862. Rs11803731 was determined to code for methionine at position 790 in 
TCHH protein. While the function of this is not known for sure, it is hypothesized that its 
function could possibly react with reactive oxygen species and result in a change in the 
structure of the protein therefore resulting in a modification to the hair follicle [44]   
Pośpiech et al. [44] evaluated six SNPs reported in the TCHH, WNT10A, and 
SLC45A2 genes in 528 individuals from Poland. During this study, they were looking at 
identifying the predictive capacity of these genes, especially relating to straight hair in 
European individuals [45]. The study this group performed confirmed the idea that 
rs11803731 (TCHH), rs73449332 (WNT10A), and rs1268789 (FRAS1) do, in fact, play a 
vital role in the morphology of hair. These three SNPs together were found to give 
greater than 80% predictability to straight hair [45]. 
Additionally, through use of genetic data obtained from the web based company 
23andMe, Inc. (a direct to consumer genetic information company), Ericksson et al. [37] 
was able to identify several novel genetic associations for physical appearance traits such 
as hair morphology, freckling, photic sneeze reflex and many others [38]. Some of the 
most relevant findings to this research focused upon the SNPs rs17646946 (near TCHH), 
rs7349332 (near WNT10A), and rs1556547 (near OFCC1). Rs17646946 (near TCHH) 
minor allele was found to reduce hair curl (therefore associated with straighter hair), this 
effect was also seen with rs1556547 (OFCC1). Rs499697 (LCE3E) whose minor allele 
was found to have the opposite effect in that it was associated with curlier hair, which 
was also similarly found with rs7349332 (WNT10A) [38]. 
The rest of the SNPs for the hair morphology assay were based upon the function 
of the genes in which they were in or near and therefore it is necessary to access the 
function of these genes. PADI3 enzyme converts L-arginine with a positive charge into a 
neutral Citrulline residue only in the presence of Calcium ions. This is true in the hair 
shaft proteins. TCHH, the most commonly associated gene with hair structure, codes for a 
structural protein localized in the inner root sheath of the hair follicle as well as the 
medulla. This gene helps to give the hair its strength by crosslinking with itself and other 
major proteins on the outer layer of the hair [32]. When this is deaminated by PADI3 it 
reduces the charge of the TCHH and allows it to be attached to the keratin filaments. 
TGM3 then crosslinks these filaments with the TCHH. These filaments are stabilized and 
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further cross-linked. A mutation at any point in this process may result in a compromise 
in the structural integrity of the hair [41].  
Huber et al. [14] performed mouse studies to determine the true function of the 
repetin gene (RPTN), also believed to have a role in hair structure. This gene has been 
identified as being fused with other cornified cellular proteins such as profilaggrin, 
trichohyalin, and hornerin, occurring late in differentiation. Through this study, they 
could hypothesize that RPTN also functions with a calcium binding protein. They also 
identified the expression of this gene in the inner root sheath of hair follicles alongside 
TCHH. It has been shown that TCHH is cross-bound to proteins in the hair shaft, 
including RPTN. These support the idea that this gene plays a role in mechanical strength 
of the hair follicle [14].  
Schlake et al. [45]  determined that Insulin Growth Factor Binding Protein 5 
(IGFBP5) in mice is a distinguishing factor in hair types. The expression of this protein 
in the medulla of the hair results in the bending zones of the hair allowing that this gene 
is a major contributor to mouse hair curving and thinning. Therefore identifying and 
studying SNPs located in this gene may also indicate if this gene plays a role in 
determining the type of hair an individual has [46].  
LIPH is a vital large triglyceride lipase, which initiates regulating and maintaining 
the hair growth cycle. Based upon the sequence variations of these genes, they can result 
in partial or complete hair loss as well as development of wooly hair, which indicates that 
this gene is a huge component of hair development. This condition of wooly hair, 
hypertrichosis, is a result of a frame shift mutation or a deletion in this gene [15]. For this 
disorder, it is also being identified in the autosomal dominant hypertrichosis, the gene 
keratin, KRT71. KRT71 has been previously identified to cause wavy/curly hair in mice, 
cats, rats, and dogs [16]. KRT74 has been identified in causing the wooly hair syndrome 
in humans. This suggests that regulation of KRT71 is performed through the activation of 
a growth factor receptor [17]. P2RY5 has also been implicated in Hypertrichosis by 
Pasternack et al. [46], from their study of a Saudi Arabian family they were able to 
determine that LPA, a bioactive lipid is a ligand for P2RY5 and therefore is the link 
between the cellular membrane and the hair follicle [47].  
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WNT10A is a member of the WNT family, which is a pancreas signaling molecule; 
these regulate cell organization during embryo development.  WNT10A has been found to 
play a role in the formation of odontoblasts, which aid in the process of forming dentin in 
teeth. A dysfunction in this gene not only results in disorders concerning the mouth and 
teeth, but also the hair and nails. EDAR variants, especially rs3827760, have been 
isolated to result in tooth and hair health [18, 19]. Based upon their roles in overlapping 
processes looking at these results could provide insight in to hair structure.  
1.7 Current SNP Genotyping Methods 
Currently, there are two major methods for the genotyping of SNPs in the forensic 
field. The current widespread method is completed using capillary electrophoresis on a 
genetic analyzer. The current methodologies for HIrisplex and HIrisPlex-S revolve 
around this technology. All the primers used for the HIrisPlex and HIrisPlex-S reactions 
are part of multiplex reactions using SNaPshot chemistry [48] (Applied Biosystems). 
These reactions begin by a flanking PCR step where an 80-200bp region around the SNP 
of interest is isolated. These regions are isolated and copied thousands of times, then 
cleaned up by Illustra ExoProStar to remove excess dNTPS and primers left from the 
reaction. Following this step, the single base extension primer hybridizes the area 
between the flanking primers and lines up to the SNP of interest. This is then extended by 
a single base, which is labeled by a florescent tag on the dideoxynucleotide triphosphate 
(ddNTPs) that can be recognized by Capillary Electrophoresis on the genetic analyzer 
and results in the termination of the PCR after a single base extension. Once this PCR is 
complete, Shrimp Alkaline Phosphatase (SAP) is used to clean up the excess ddNTPs 
present in the reaction. In the final step, the sample is placed on the analyzer with 
formamide for suspension and capillary travel along with LIZ an internal size standard. 
This will then produce an electropherogram that can be easily binned and genotyped.  
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Figure 4 Santagata et al depiction of Snapshot Multiplex Reaction  
 
The second, and newest method is Massive Parallel Sequencing (MPS), which is a 
four-step process that results in the sequencing of millions of fragments of DNA. The two 
main types of MPS systems are the Ion Torrent, a pH based system, and the Miseq a 
sequencing by synthesis system. For the intent of this thesis, we will focus all our 
Massive Parallel Sequencing on the Miseq. 
The process for the Miseq begins with library preparation in which DNA is 
fragmented based upon primers designed to specific regions that contain adapter 
sequences in addition to the primer sequence. PhiX, which is spiked in during this 
procedure, operates as a control library for the cluster generation, sequencing, and 
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alignment, therefore allowing us to determine an accurate error rate within our reaction.  
These adapters are specific to the technology being used and allow for the fragments to 
adhere to the flow cell. Once these are cleaned up, the next step is cluster generation. 
This process is completed by the loading of the library onto the polyacrylamide flow cell 
that contains a lawn with complementary oligos to the adapters on the library that was 
assembled. Bridge amplification occurs to form clusters of amplicons. These clusters are 
then read using a sequence by synthesis method.  This method uses four fluorescently 
labeled nucleotides. A single dNTP is added to the sequencing chain of nucleic acids. 
This stops polymerization and the dye is then imaged and then an enzymatic reaction is 
used to cleave this dNTP so that the next nucleotide can be incorporated. This step results 
in sequencing of these fragments like CE sequencing [27]. This is then imaged on the 
flow cell and based upon the wavelength and intensity, a base is recorded.  The fragments 
are then de-multiplexed in order for them to be separated into each individual indices that 
correspond with the individual samples.  The final step is to then align to a custom 
genome and analyze the fragments.  
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CHAPTER 2. METHODS AND MATERIALS: GLOBAL SKIN 
COLOR PREDICTION MODEL INCLUDING HIRISPLEX-S 
DESIGN AND VALIDATION ON CAPILLARY 
ELECTROPHORESIS 
2.1 Sample Collection and Skin Color Phenotyping 
Samples that were contributed towards this study were collected in compliance 
with IRB#1409306349, 329 US samples were used along with 1625 samples previously 
genotyped from Poland, Ireland, and Greece for the model validation. For the US samples, 
5ml of saliva was collected from each individual, after the individual had consented to 
the study. Each participant filled out a questionnaire and had three hairs removed from 
the back of their head. Photographs were then taken of each participant’s externally 
visible characteristics with a Nikon D5300 camera with AF-S Micro Nikon 60mm lens 
and two Nikon Wireless Speedlight SU-800- Remote SB-R200 flashes. Once the photos 
were complete, pigmentation measurements were taken with a Konica Minolta 
700d/600d Spectrophotometer which measures wavelengths from 400-700nm, Melanin 
Index, and L*ab values. The spectrometer measurements for L*ab were as follows: 
74.14-60.36 for White, comprising 132 samples; 59.32-40.04 for Intermediate, 
comprising 43 samples; 39.75-29.99 for Black, comprising 20 samples. 4ml of saliva was 
then added to 1ml of DNA lysis buffer and stored at -20ºC until DNA extraction took 
place. 1ml of saliva was also added to 1ml of RNAlater (Fisher Scientific International 
Inc., Hampton, NH) and stored at -20ºC until RNA extraction took place. The hair 
samples were stored at -20ºC in RNAlater as well for future use. The photo of the 
SpyderCHECKRTM calibration card was taken at each collection to help standardize the 
lighting over multiple collections.  
2.2 DNA Extraction, Quantification & SNP Genotyping 
To perform the DNA extraction, 1ml of the saliva sample/lysis buffer mixture, 
15µl of Proteinase K (New England Biolabs, Ipswich, MA), and 130µl of 10% SDS (Dot 
Scientific Inc., Burton, MI) were added to a 2ml tube and incubated on an Eppendorf 
Thermomixer set to 300 rpm at 37°C overnight. Once this incubation was complete, 
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200µl of 0.5M NaCl (Dot Scientific Inc.) was added, inverted, and then incubated at 
room temperature for 10 minutes. The samples were then centrifuged for 12 minutes at 
10ºC at maximum speed (16200cfg). The supernatant was transferred to a new tube and 
an equal volume of 100% isopropanol (Fisher Scientific International Inc., Hampton, NH) 
was added. It was then incubated for 10 minutes at room temperature, and then 
centrifuged for 15 minutes at 10ºC at maximum speed (16200cfg). The supernatant was 
discarded and the pellets were washed. The supernatant was discarded and the wash 
repeated with 500µl 70% ethanol (Decon Laboratories Inc., King of Prussia, PA) after 
inversion. They were then centrifuged again for 5 minutes. After the second wash, the 
supernatant was removed and the pellets were dried for 10 minutes. The samples were 
then re-suspended in 30µl of deionized H2O and stored at -20°C or -80°C until further 
use.  
Once the extraction was complete, the samples were quantified using the Qubit 
Fluorometer following the standard protocol for the DNA High Sensitivity Assay Kit 
(Fisher Scientific International Inc., Hampton, NH). These samples were genotyped using 
the HIrisPlex, HIrisPlex-S, and Snipper systems [2, 3].  
The assays were set up based upon the standard steps for SNaPshot chemistry. For 
the HIrisPlex-S reaction the initial flanking primers are used to amplify an area surround 
the SNP of interest by anywhere from 80-200bp. The first 3 MC1R primers were added at 
a concentration of 0.5µM for both the forward and reverse flanking primers. The 
remaining 14 primers were added at a concentration of 0.4µM of both the forward and 
reverse flanking primers. 1µl of 10X PCR gold buffer (Fisher Scientific International Inc., 
Hampton, NH), 1µL of 25µM MgCl2 (Fisher Scientific International Inc., Hampton, NH), 
0.22µL of 10mM dNTPs (Fisher Scientific International Inc., Hampton, NH), 3.64µL of 
deionized H20 and 0.3µL of 5U/µL AmpliTaq Gold (Fisher Scientific International Inc., 
Hampton, NH) were added per sample. 1µL of DNA was then added per reaction as well. 
PCR amplification was performed to amplify the regions of interest per the following 
standards at 95°C for 10 minutes, then 33 cycles of 95°C for 30 seconds then 62°C for 30 
seconds, and finally 61°C for 5 minutes. The sample was then held at 15°C until the next 
step was performed. All of this was performed on the Eppendorf Mastercycler Nexus. For 
HIrisPlex-S, the appropriate amount of primers, 1µl of 10X PCR gold buffer (Fisher 
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Scientific International Inc., Hampton, NH), 1µL of 25µM MgCl2 (Fisher Scientific 
International Inc., Hampton, NH), 0.22µL of 10mM dNTPs (Fisher Scientific 
International Inc., Hampton, NH), 2.38µL of deionized H20 and 0.3µL of 5U/µL 
AmpliTaq Gold (Fisher Scientific International Inc., Hampton, NH) were added per 
sample. The protocol for HIrisPlex and HIrisPlex-S only differ at the annealing/extension 
step in the PCR cycle, in that instead of 62ºC, HIrisPlex requires those two steps to be at 
61ºC to be in the optimal range for annealing of the primers. 
From this point Illustra ExoProStar (GE Healthcare, Waukesha, WI) was used to 
clean up the samples before the single base extension reaction was performed. 2µL of the 
ExoProStar was added to 5µL of sample and then placed on the thermocycler at 37°C for 
45 minutes and then 80°C for 15 minutes. The sample was then held at 15°C until the 
next step was performed.  
The third step in the process is the actual single base extension reaction. Each 
SNP’s single base extension primer was added per the concentrations on the protocol in 
Tables 2 and 3 in Appendices B and C. For HIrisPlex, the primer mixture was added at 
1.74µL, 0.26µL H2O, and 1µL of SNaPshot (Fisher Scientific International Inc., 
Hampton, NH) are added along with 2µL of sample. For HIrisPlex-S, the primer mixture 
was added at 1.77µL, 0.225µL H2O, and 1µL of SNaPshot (Fisher Scientific International 
Inc.) are added along with 2µL of sample. The sample was then placed on the 
thermocycler at 96°C for 2 minutes, then 25 cycles of 96°C for 10 seconds, 50°C for 5 
seconds and 60°C for 30 seconds. The sample was then held at 15°C until the next step 
performed. 
The final step in the amplification process was the final clean up step using 
Shrimp Alkaline Phosphatase (SAP) (Fisher Scientific International Inc.,). 1µl of SAP is 
added to each sample and then placed back on the thermocycler at 37°C for 45 minutes 
followed by 75°C for 15 minutes. The sample was then held at 15°C until it was placed 
on the analyzer.  
The purified samples are then processed and visualized by the Applied 
Biosystems 3500 Genetic Analyzer using POP7 (Fisher Scientific International Inc.,) 
with a 50cm array. 1µL of sample was added to 8.9µL of Formamide (Fisher Scientific 
International Inc.,) and 0.1µL of GeneScan Size Standard LIZ (Fisher Scientific 
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International Inc.,) per plate well. These samples were visualized using Applied 
Biosystems GeneMapper software.  
2.3 Skin Color Phenotyping and Prediction Modeling 
The Fitzpatrick scale was applied by a dermatologist to accurately phenotype the 
skin pigmentation of the individuals used for model validation [49]. The typical 
Fitzpatrick scale breaks down skin types into six groups. The groups are based upon the 
ability of the individual to tan or burn in the sun in addition to pigmentation [50]. 
Narrowing these categories down to both 3 and 5 categories, a statistical model was built 
that could then be compared to previous skin color prediction models such as Maronas et 
al. [3]. In this paper [49], we genotyped and assessed 1159 individuals from South 
Poland, 347 from Ireland, 119 from Greece, and 329 from the United States at 77 markers. 
Along with these groups we also included 71 individuals from the HGDP-CEPH 
reference set.  Due to the requirement for a complete set of genotypes the number of 
samples was then reduced to 1423. These individuals were phenotyped using the 
Fitzpatrick scale [49].The skin types in the Fitzpatrick scale range from skin type 1(pale-
white skin, no ability to tan), type 2 (white skin, minimal ability to tan, type 3 (light 
brown skin, tanning ability), type 4 (moderate skin, tanning ability), type 5 skin (dark 
brown skin, tanning ability, and type 6 (deep pigmentation of the skin, dark brown to 
black).  
329 samples from an in-house FDP database were used to represent samples from 
the United States (while their parents were from outside the United States). These 
included individuals who were from Nigeria, Mexico, Argentina, Columbia, India, 
Bangladesh, Cuba, Palestine, Canada, China, Honduras, Germany, Philippines, Russia, 
Sudan, Japan, Saudi Arabia, Pakistan, El Salvador, Spain, Haiti, South Korea, and 
Vietnam. This information was self-reported on their initial questionnaire. In terms of 
phenotyping their skin pigmentation, everyone’s 2D photograph (arm picture) along with 
tanning information that was recorded on their questionnaire was graded by a 
dermatologist to determine the appropriate Fitzpatrick rating that their skin should 
receive.  
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77 skin pigmentation SNPs were tested in their predictability for skin 
pigmentation. A partial correlation (correcting for sex and ancestry) resulted in 53 
statistically significant SNPS. From this point AUC values were used to determine the 
best combination of SNPs to gain the most substantial amount of pigmentation 
information.  From this 36 SNPs from 16 genes were selected; rs1426654 (SLC24A5), 
rs12203592 (IRF4), rs1805007 (MC1R), rs1805008 (MC1R), rs11547464 (MC1R), 
rs885479 (MC1R), rs228479 (MC1R), rs1805006 (MC1R), rs1110400 (MC1R), 
rs1126809 (MC1R), rs3212355 (MC1R), rs1800414 (OCA2), rs1800407 (OCA2), 
rs12441727 (OCA2), rs1470608 (OCA2) , rs1545397 (OCA2),  rs16891982 (SLC45A2), 
rs28777 (SLC45A2), rs1667394 (HERC2), rs2238289 (HERC2), rs1129038 (HERC2), 
rs12913832 (HERC2), rs6497292 (HERC2), rs1042602 (TYR), rs1393350 (TYR), 
rs6059655 (RALY), rs8051733 (DEF8), rs2378249 (PIGU), rs6119471 (ASIP), rs2402130 
(SLC24A4), rs17128291(SLC24A4), rs12896399 (SLC24A4), rs683(TYRP1), rs12821256 
(KITLG), rs3114908 (ANKRD11), and rs10756819 (BNC2). 194 individuals that had not 
been previously used to generate the model were then used to compare the skin color 
prediction performance of both the HIrisPlex (36 of the above variants were genotyped) 
and Snipper models [2,3] (where 10 variants were typed). The Snipper model includes 
the following 10 SNPs rs10777129 (KITLG), rs13289 (SLC45A2) and rs16891982 
(SLC45A2), rs1408799 (TYRP1), rs1426654 (SLC24A5), rs1448484 (OCA2), rs2402130 
(SLC24A4), rs3829241 (TPCN2), rs6058017 (ASIP) and rs6119471 (ASIP).  
2.4 Optimization and Developmental Validation of the HPS Assay 
The HIrisPlex-S assay requires two individual SNaPshot reactions to achieve a 
complete profile for the 36 required skin color associated SNPs: rs1426654 (SLC24A5), 
rs12203592 (IRF4), rs1805007 (MC1R), rs1805008 (MC1R), rs11547464 (MC1R), 
rs885479 (MC1R), rs228479 (MC1R), rs1805006 (MC1R), rs1110400 (MC1R), 
rs1126809 (MC1R), rs3212355 (MC1R), rs1800414 (OCA2), rs1800407 (OCA2), 
rs12441727 (OCA2), rs1470608 (OCA2) , rs1545397 (OCA2),  rs16891982 (SLC45A2), 
rs28777 (SLC45A2), rs1667394 (HERC2), rs2238289 (HERC2), rs1129038 (HERC2), 
rs12913832 (HERC2), rs6497292 (HERC2), rs1042602 (TYR), rs1393350 (TYR), 
rs6059655 (RALY), rs8051733 (DEF8), rs2378249 (PIGU), rs6119471 (ASIP), rs2402130 
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(SLC24A4), rs17128291(SLC24A4), rs12896399 (SLC24A4), rs683(TYRP1), rs12821256 
(KITLG), rs3114908 (ANKRD11), and rs10756819 (BNC2). The first assay is the 
previously published HIrisPlex assay designed by Walsh et al. generating the 24 DNA 
variants using 17 primer sets [6]. The second 17-plex consists of the remaining variants. 
The flanking primers of SNPs rs10756819, rs1126809, rs6497292, rs1545397, rs6059655, 
and rs12441727 did not undergo successful amplification during the initial design by 
collaborators and were therefore redesigned at the Walsh laboratory. The single base 
extension (SBE) primers for rs3114908, rs10756819, rs1126809, and rs6059655 we also 
redesigned due to unsuccessful amplification. Details of these new designs can be found 
in Table 2 in Appendix A. 
2.5 Concordance of SNaPshot Assay Using Casework Samples 
A concordance casework set (30 samples) was received from a collaborating site 
to ensure the assay worked accurately despite the location, individual running the assay, 
or machine the assay was performed on. The assays were performed on an Applied 
Biosystems 3130 Genetic Analyzer at the collaborating site, the Netherlands. Therefore, 
it was essential to run the same samples on a newer platform, Applied Biosystems 3500 
Genetic Analyzer to ensure that the assay’s efficiency is the same regardless of the 
change in parameters. These 30 samples were run following the previously described 
HIrisPlex-S protocol. The profiles for these samples were obtained using Applied 
Biosystems GeneMapper software. An interpretative threshold of 50 RFU was used to 
ensure accuracy when identifying the profile 
2.5.1 Sensitivity Testing for Biological Assay Concordance 
 The sensitivity of this assay was assessed on both the 3130 and 3500 Genetic 
Analyzers. The concentrations in which the samples were evaluated at were 1ng/µL, 500 
pg/µL, 250 pg/µL, 125 pg/µL, 60 pg/µL and 30 pg/µL. The control samples created from 
DNA extracted from collection participants labeled K1 and C1 were diluted to 
appropriate concentrations by taking triplicate measurements using the Qubit fluorimeter. 
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2.5.2 Species Specificity Testing  
Species specificity testing was performed to ensure that the primers designed were 
indeed human specific. This system was tested against cat, chimp, dog, mouse, and pig 
DNA quantified to 1ng/µl. All samples were obtained externally from pet samples and 
extracted in house apart from the chimp sample which was obtained from Dr. Brenda 
Bradley of George Washington University and the mouse sample was obtained from Dr. 
Benjamin Perrin of Indiana University Purdue University Indianapolis. 
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CHAPTER 3. METHODS AND MATERIALS: HAIR 
MORPHOLOGY SNP AND GENE ASSOCIATION THROUGH 
MASSIVE PARALLEL NEXT GENERATION SEQUENCING 
3.1 Sample Collection and phenotyping, DNA Extraction, and Quantification 
The samples for this study were collected as previously mentioned in section 2.1 as 
they are from an in-house FDP database. 1026 samples were used for this study. The 
extraction and quantification of these samples were completed as described in section 2.2. 
These samples were phenotyped using a self-assessment of their hair structure as to 
whether they categorize it as wavy, straight, or curly. 387 individuals identified as having 
Very Straight Hair, 144 individuals identified as having Curly Hair/ Rings of Curls, and 
495 individuals identified as having Light Waves.  
3.2 Hair Morphology SNP Genotyping 
A custom Miseq Assay consisting of 91 primers that can be found in Table 5 in 
Appendix D for the initial PCR was ran for all samples mentioned in section 3.1. Primers 
were split into 3 groups of around 30 primers, PCR performed, and then combined post 
cleanup. The thermocycler settings for this reaction followed a touchdown PCR protocol. 
Protocols can be found in Tables 5,6, and 7 in Appendices E, F, and G. 
3.3 Bead Clean Up Solution Preparation 
A 5M NaCl solution was prepared along with a 40% PEG-8000 solution. 1ml of 
Sera-Mag Speed Beads were isolated via magnet from their suspension and then washed 
twice and resuspended in 1ml deionized water. The suspension solution was then 
prepared by adding 10 ml 5M NaCl, 9ml of nuclease free water and 1ml of the clean 
beads. 30ml of 40% PEG was then added to the bead mixture and vortexed, allowing for 
the beads to suspend. The mixture was then stored in a light protected tube in the 4 C 
refrigerator until use. This protocol developed by Rohland and Reich on high-throughput 
DNA sequencing in 2017 [51], was adapted and modified to fit our assay requirements. 
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3.4 Execution of an MPS Assay for Hair Morphology 
384 samples were dispersed amongst four plates and then ran for each of the three 
primer groups to total 12 plates. All DNA had been previously diluted to quantify around 
20ng/µL as reported on the Qubit. The primers were added in the concentrations 
specified on the three protocols attached in Tables 5, 6, and 7 in Appendices E, F, and G. 
1µl of 10X PCR gold buffer, 1µL of 25uM MgCl2, 0.22µL of 10mM dNTPs, 3.64µL of 
deionized H20 and 0.3µL of 5U/µL AmpliTaq Gold were added per sample. 1µL of DNA 
was then added per sample as well. This PCR amplification was used to amplify regions 
of interest according to the following standards at 95 °C for 10 minutes, then 28 cycles of 
95°C for 30 seconds, a touch down starting at 64 °C for 40 seconds decreasing at 0.3 
degrees a cycle and 60 °C for 5 minutes. This was then held at 15°C.  
Once this reaction was successful in amplifying the regions of interest, 5µL of 
each product of the 3 primer group plates was added together in the same plate and along 
with 5µL of deionized water to dilute the samples.  
To prepare the reaction for amplicon sequencing it was then necessary to clean up 
the plates using the magnetic bead suspension prepared previously. 3 times the amount of 
the sample is the amount of beads (typically 45µL) that were added to each sample and 
mixed thoroughly to ensure that the DNA properly adheres to the beads. An 8-minute 
incubation allowed for this binding of the beads to the DNA to take place. Once the 
mixture was briefly spun down, the samples were placed on a magnetic stand which 
forced the beads along with the DNA to the bottom and side along the magnet. The 
supernatant was discarded while on the stand and then washed with 90µL of 80% Ethanol. 
The ethanol was removed in the same fashion and then the wash repeated. The samples 
were air dried for 30 seconds and then resuspended in 25µL of purified water after a 5-7-
minute incubation.  
The second round of PCR was then performed to adhere the index sequences to 
each sample as a unique identifier in order to demultiplex each individual sample when 
pooled. For each well 5µL of KAPA master mix (KAPA Biosystems, Wilmington, MA), 
1µl of each index (both forward and reverse to total 2 µL), 2 µL of H20, and 1 µL of 
DNA were added to each well of the plate. The samples were placed on the Eppendorf 
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Mastercycler Nexus SX1 98 °C for 2 minutes, then 12 cycles of 98 °C for 30 seconds, 
72°C for 30 seconds and 72 °C for 5 minutes and then held at 15ºC. 
Following this step, the products were cleaned up adhering to the exact same 
procedure as mentioned above, but all reagents were cut in half due to the decreased 
volume of sample. To verify that the products of the PCR reactions were still present 
after this clean up, the products were ran on the Bioanalyzer to ensure that there were 
indeed products between 100bp and 300bp.  
To successfully sequence these samples, the products were pooled, diluted and 
quantified to finalize library preparation. 5µL of each sample was pooled and then 
quantified using the Qubit fluorometer. The table found in Table 9 in Appendix H 
[52]was used then to calculate an accurate dilution to a 2nM concentration. Denaturing 
the library then required 5µL of 0.2N NaOH to 5µL of the 2nM library. After a brief spin 
down, this was incubated for 5 minutes at room temperature. It was essential after the 
denaturation to then dilute the sample again down to 10pM with 990µL of Hybridization 
Buffer (Illumina, San Diego, CA) provided with the Illumina Nextera XT Version 2 Kit 
(Illumina, San Diego, CA).  This denatured library was then diluted again to 8nM using 
480µL of library and 120µL of Hybridization Buffer with a pulse vortexing.  
Now that the library was properly diluted, the PhiX control (Illumina, San Diego, 
CA) provided by Illumina was added to standardize the reaction. The 4nM PhiX library 
5µL was added to 5µL of 0.2N NaOH. The control was then vortexed, spun down, and 
incubated for 5 minutes. The control was then diluted again using 10µL of PhiX Library 
and 990µL of Hybridization Buffer to a final concentration of 20pM PhiX library. The 
final dilution to 12.5 pM was then performed using 375µL of the previously diluted PhiX 
library and 225µL of Hybridization Buffer. The last step before adding the samples to the 
Miseq cartridge is to add a 15% PhiX spike in to the custom library prepared via 90µL 
PhiX and 510µL of the library.  
Once the library was prepared and then the cartridge is thawed, 600ul of the 
prepared library was loaded into the ‘Load Samples’ reservoir on the cartridge. The 
cartridge was then ran on ‘Research Use Only’ Mode through the Nextera XT sequencing.  
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3.5 File Conversion, Alignment and Genotype Extraction 
To evaluate the data that was synthesized as a result of this Miseq run, a custom 
genome had to be assembled first to align the samples with. All this assembly and 
conversion was performed on an iMac in a UNIX environment. This custom genome 
allows for the isolation and alignment of the DNA to areas of interest as opposed to the 
whole genome, making evaluation of data a much simpler task. For the type of data that 
was produced referred to as amplicons, aligning these to the entire genome would be 
error prone and memory intensive. Instead, by assembling a genome appropriate for this 
assay we can ensure that the amplicons align exactly where intended. 
The first step in this conversion process is the conversion of the reference genome 
file to the “. fai” format or fasta index format allowing the file to be searchable. This is 
done through a program called SAM tools [53]. A fasta file is then created in order to 
generate custom sites of interest. After the file is in fasta format it was then necessary to 
use the program BWA (Burrows-Wheeler Aligner) to index the fasta file [54].The output 
file from the Miseq is in the form of a “.fastq” file. Two fastq files are produced by the 
Miseq for each sample and it contains either the forward or reverse sequencing read for 
that sample. From this file, conversion must first be completed to visualize the data. This 
then allows for the sequencing files created by the Miseq to be aligned via BWA to 
produce a sequence alignment map (.sam file) [54]. Once the “.sam” file is produced a 
program called Picard tools is needed to convert the “.sam” file to a binary format file 
(.bam file) [55]. Once converted, the bam file must be sorted. In addition to sorting the 
bam file, it is also necessary to generate a “.dict” file that contain contig name and sizes 
in order for the Genome Analysis ToolKit (GATK) to effectively recognize the custom 
genome [56].  
Now that the file was converted and sorted as a bam file along with a searchable 
reference file, it was necessary to convert the Miseq generated files to the final file type 
of variant call files (.vcf file). To do so, it was necessary to install bcftools and vcflib. 
SAMtools, was used to convert the file to the “.vcf” format before exporting [53]. Now 
that the “.vcf” file had been created, it was then essential to install genomeanalysisTK.jar 
for the GATK program, this allows the compilation and visualization of the SNP 
genotypes at specific locations [56]. Based upon the visible results at this stage, 
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Integrative Genomics Viewer (IGV), a genome viewing software, was used to check and 
evaluate any SNPs in which the program was unable to successfully call a genotype for 
[57]. This allowed for the output of the genotypes for all 1130 individuals in the assay. 
All coding done for this portion of this thesis can be found in Appendix I. 
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CHAPTER 4. METHODS AND MATERIALS: MIGRATING 
HIRISPLEX- S TO THE MASSIVE PARALLEL NEXT 
GENERATION SEQUENCING PLATFORM 
4.1 Sample Collection, Extraction, and Quantification 
The samples for this study were collected as previously mentioned in section 2.1 
as they are from the same database. The extraction and quantification of these samples 
were performed as described in section 2.2.  
4.2 Development of a Custom Developmental Validation Set 
SWGDAM guidelines required this set to address sensitivity, species specificity, 
mixture assessment, simulated casework, stability studies, population studies, and 
concordance. To see the distribution of these samples as well as their individual 
information refer to Table 10 in Appendix J. All sample concentrations were determined 
by qPCR via InnoQuant Human DNA Quantification and Degradation Assessment Kit 
[58]. 
4.2.1 Sensitivity 
For sensitivity, three samples of control DNA, 9947A, 9948, and 007, were 
diluted to concentrations of 1pg, 5pg, 10pg, 25pg, 50pg, 100pg, 250pg, 500pg, and 1ng 
repeated in triplicate. 
4.2.2 Species Specificity  
This system was tested against cat, chimp, dog, mouse, and pig DNA at 1ng/µl.  
All samples were obtained externally from pet samples and extracted in house apart from 
the chimp sample, which was obtained from Dr. Brenda Bradley of George Washington 
University, and the mouse sample was obtained from Dr. Benjamin Perrin of Indiana 
University Purdue University Indianapolis. 
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4.2.3 Mixture Assessment  
Mixture assessment was tested at length in ratios of 1:1, 1:2, 1:5, and two sets of 
1:10. Two three person mixtures were also included in 1:1:2 and 2:1:2 ratios. The 
individuals used in these mixtures represent a variety of population set such as European, 
African, Chinese, Mexican, and Iranian. They also represent a variety of hair 
pigmentations ranging from blond to dark brown and eye pigmentations ranging from 
blue to brown. In addition to the physical traits of hair and eye pigmentation, their skin 
pigmentations also varied from type 1 to type 5 on the HIrisPlex-S skin pigmentation 
scale. 
4.2.4 Simulated Casework 
For the simulated casework, samples were manufactured to mimic dried and 
degraded blood, wet blood, DNA with heme contamination, dried and degraded saliva, 
wet saliva, touch DNA, hair, vaginal swab, and vaginal swab mixture with semen. 
4.2.5 Stability Samples 
To address the ability of the assay to perform on degraded samples two control 
samples were degraded using DNase at time points of 0 minutes, 5 minutes, 10 minutes, 
20 minutes, and 40 minutes. The degradation of these samples was ensured through 
analysis of these samples using HIrisPlex on the genetic analyzer before use on the Miseq.   
4.2.6 Population Studies  
  For the final aspect of assessing the assay’s performance on various populations a 
variety of samples were included at a 500pg concentration from various populations such 
as European, Vietnamese, Mexican, African, Chinese, Panamanian, and Iranian. These 
individuals also represent the same widespread distribution of physical attributes as 
previously mentioned.  
4.2.7 Concordance 
The final assessment needed under SWGDAM guidelines is concordance. To 
address concordance for an assay such as this one, with MPS it is necessary to ensure that 
this assay performs well on both the Illumina Miseq and the Ion Torrent. To do this, 
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concordance plates were sent to three European collaborators with the respective 
instruments. A complete validation plate was sent along with two randomly selected 
concordance plates. These concordance plates contained 14 500pg samples, 7 degraded 
samples, 8 mock casework samples, 3 specifies specificity samples, 1 three-person 
mixture sample, 3 1:1 two-person mixture samples, 6 1:10 two-person mixture samples, 3 
1:2 two-person mixture samples, and 6 1:5 two-person mixture samples.  
4.3 HIrisPlex-S SNP Genotyping using MPS 
A custom Miseq Assay consisting of 41 primers can be found in Table 12 located 
in Appendix L for the initial PCR which was ran for all samples mentioned in section 4.1. 
The thermocycler settings for this reaction followed a touchdown PCR protocol.  
For the initial optimization run, 96 samples from the previously mentioned 
validation set were ran. 24 500pg samples were ran in duplicate along with 35 mixture 
samples ranging from ratios of 1:1, 1:2, 1:5, and 1:10. This run also included 2 three 
person mixtures and 11 mock casework samples. The distribution, population, eye color, 
hair color, and skin type for these individuals can all be found in Table 11 located in 
Appendix K. All DNA had been previously diluted to quantified through InnoQuant. The 
primers were added in the concentrations specified on the protocol attached in Table 13 
in Appendix M. Included in the primer design were a forward adapter of 
TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG; and a reverse adapter of 
GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG. 1µl of 10X PCR gold buffer, 
1µL of 25uM MgCl2, 0.22µL of 10mM dNTPs, 2.45µL of deionized H20 and 0.4µL of 
5U/µL AmpliTaq Gold were added per sample. 1µL of DNA was then added per sample 
as well. This PCR amplification was used to amplify regions of interest according to the 
following standards at 10 minutes at 95ᴼC, followed by 34 cycles of 30 seconds at 95ᴼC 
then touchdown at 62°C decreasing by 0.3 for 30 seconds and then 60ᴼC for 10s, finally 5 
minutes at 60°C.   
To prepare the reaction for amplicon sequencing it was then necessary to clean up 
the plates using the magnetic bead suspension prepared previously. 1.25 times the amount 
of the sample is the amount of beads that were added to each sample and mixed 
thoroughly to ensure that the DNA properly adheres to the beads. An 8-minute incubation 
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allowed for this binding of the beads to the DNA to take place. Once the mixture was 
briefly spun down, the samples were placed on a magnetic stand for 5 minutes, this 
forced the beads along with the DNA to the bottom and side along the magnet. The 
supernatant was discarded while on the stand and then washed with 200µL of 80% 
Ethanol. The ethanol was removed in the same fashion and then the wash was repeated 
after 30s. The samples were air dried for 2-5 minutes and then resuspended in 25µL of 
purified water after a 5-7-minute incubation.  
The second round of PCR was then performed to adhere the index sequences to 
each sample as a unique identifier to demultiplex each individual sample when pooled. 
For each well 5µL of KAPA master mix (KAPA Biosystems, Wilmington, MA), 1µl of 
each index (both forward and reverse to total 2 µL), 2 µL of H20 and 1 µL of DNA were 
added to each well of the plate. The samples were placed on the Eppendorf Mastercycler 
Nexus SX1 98 °C for 2 minutes, then 12 cycles of 98 °C for 30 seconds, 72°C for 30 
seconds and 72 °C for 5 minutes and then held at 15ºC. 
To successfully sequence these samples, the products were pooled, diluted and 
quantified to finalize library preparation. 5µL of each sample was pooled and then 
quantified using the Qubit fluorimeter. The table found in Table 9 located in Appendix H 
[52] was used then to calculate an accurate dilution to a 2nM concentration. Denaturing 
the library then required 5µL of 0.2N NaOH to 5µL of the 2nM library. After a brief spin 
down, this was incubated for 5 minutes at room temperature. It was essential after the 
denaturation to then dilute the sample again down to 10pM with 990µL of Hybridization 
Buffer provided with the Illumina Nextera XT Version 2 Kit. This denatured library was 
then diluted again to 8nM using 480µL of library and 120µL of Hybridization Buffer 
with a pulse vortexing.  
Now that the library was properly diluted, the PhiX control (provided by Illumina 
was added to standardize the reaction. The 4nM PhiX library 5µL was added to 5µL of 
0.2N NaOH. The control was then vortexed, spun down, and incubated for 5 minutes. 
The control was then diluted again using 10µL of PhiX Library and 990µL of 
Hybridization Buffer to a final concentration of 20pM PhiX library. The final dilution to 
12.5pM was then performed using 375µL of the previously diluted PhiX library and 
225µL of Hybridization Buffer. The last step before adding the samples to the Miseq 
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cartridge is to add a 20% PhiX spike in to the custom library prepared via 120µL PhiX 
and 480µL of the library.  
Once the library was prepared and then the cartridge is thawed, 600ul of the 
prepared library was loaded into the Load Samples reservoir on the cartridge. The 
cartridge was then ran on ‘Research Use Only’ Mode through the Nextera XT sequencing.  
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CHAPTER 5. RESULTS AND DISCUSSION: GLOBAL SKIN 
COLOR PREDICTION MODEL INCLUDING HIRISPLEX-S 
DESIGN AND VALIDATION ON CAPILLARY 
ELECTROPHORESIS 
5.1 Global Skin Color Prediction Model   
77 SNPs were assessed for their value in predicting skin pigmentation in 2025 
individuals. A partial correlation (correcting for sex and ancestry) resulted in 53 
statistically significant SNPs. From this point AIC values were used to determine the best 
combination of SNPs to gain the most substantial amount of pigmentation information 
resulting in 36 SNPs from 16 genes being selected; rs1426654 (SLC24A5), rs12203592 
(IRF4), rs1805007 (MC1R), rs1805008 (MC1R), rs11547464 (MC1R), rs885479 (MC1R), 
rs228479 (MC1R), rs1805006 (MC1R), rs1110400 (MC1R), rs1126809 (MC1R), 
rs3212355 (MC1R), rs1800414 (OCA2), rs1800407 (OCA2), rs12441727 (OCA2), 
rs1470608 (OCA2) , rs1545397 (OCA2),  rs16891982 (SLC45A2), rs28777 (SLC45A2), 
rs1667394 (HERC2), rs2238289 (HERC2), rs1129038 (HERC2), rs12913832 (HERC2), 
rs6497292 (HERC2), rs1042602 (TYR), rs1393350 (TYR), rs6059655 (RALY), rs8051733 
(DEF8), rs2378249 (PIGU), rs6119471 (ASIP), rs2402130 (SLC24A4), 
rs17128291(SLC24A4), rs12896399 (SLC24A4), rs683(TYRP1), rs12821256 (KITLG), 
rs3114908 (ANKRD11), and rs10756819 (BNC2) for model building. 329 individuals 
were genotyped in our laboratory at the 41 SNPs (for eye, hair, and skin prediction) to 
help produce a more global model due to their unique allele combination.  
After the quality of the samples were evaluated a set of 1423 individuals used to 
produce the prediction model for the HIrisPlex-S system as a five category based 
prediction system [49].  The distribution of the samples was Very Pale 98 individuals, 
Pale 631 individuals, Intermediate 555 individuals, Dark 49 individuals, and Dark-Black 
90 individuals. Upon analyzing the results for skin categories, it was most beneficial to 
combined categories 3 and 4 for our system, reducing it to a five-category system; Very 
Pale, Pale, Intermediate, Dark, and Dark-Black.  
To represent the global population, splitting the light category is advantageous for a 
more accurate physical prediction rather than maintaining the same 3 category system. 
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When this is done the AUCs were as follows: 0.97 ±0.03for Dark- Black, 0.87 ±0.1 for 
Dark, 0.73 ±0.03 Intermediate, 0.72 ±0.03 Pale, 0.74 ±0.05 Very Pale. Based upon this 
data, we are able to conclude that our prediction model and assay will achieve DNA-
based skin pigmentation prediction regardless of biographical ancestry.  
5.1 Comparison of HIrisPlex-S to Maroñas ‘Snipper’ Skin Color Model 
An individual set of 194 individuals were genotyped for the 36 SNPs for HIrisPlex-
S as well as the 10 predictors SNPs for Maronas et al.[3]. On the dataset using the 
Maronas et al. model, AUC values using 194 individuals were generated. This resulted in 
the AUC values as follows: 0.75 for White, 0.55 for Intermediate, and 0.67 for Black. 
When comparing these AUCs to those obtained using our modeling system for the 3-
category system used in the Maronas model, the AUC increased to 0.79 for White, 0.66 
for Intermediate, 0.89 for Black. However, the highest AUC values were achieved when 
our 36 SNP model employing the Fitzpatrick scale was used with AUC values of 0.9 for 
Light, 0.91 for Dark, and 0.91 for Dark-Black. Therefore, indicating that our model 
outperformed and improved the skin color predictions given by the model provided by 
Maronas et al. [3].   
5.2 HIrisPlex-S Design and Validation on Capillary Electrophoresis  
As for the HIrisPlex-S design, the original design was obtained from previous 
work with a collaborating site in the Netherlands. While optimizing the initial set up 
using the SNapShot multiplex assay, it was found that the flanking primers of SNPs 
rs10756819, rs1126809, rs6497292, rs1545397, rs6059655, and rs12441727 did not 
undergo successful amplification under singleplex or multiplex conditions and therefore 
it was necessary to redesign or adjust the concentrations of these primers as required. 
Following this, the single base extension (SBE) primers for rs3114908, rs10756819, 
rs1126809, and rs6059655 we also redesigned due to unsuccessful amplification under 
singleplex and multiplex conditions as well. 
Flanking primers for SNPs rs10756819, rs1126809, rs6497292, rs1545397, 
rs6059655, and rs12441727 were initially unsuccessful during amplification, therefore a 
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step-by-step process was used to create and test the new primers. In order to design these 
flanking primers the SNP of interest and the surrounding area were identified on the 
NCBI SNP database, dbSNP [59]. Once the area was identified, the surrounding SNPs 
and INDELS were marked and then the sequence was placed into Primer3Plus in order to 
isolate the specific flanking primers of optimal temperature and size [60]. The primers are 
then ran through the ePCR program Bisearch to ensure that the specificity of the primer 
in that it only binds at the specific spot in the genome that it is intending to isolate [61]. 
For the flanking primers, the entire set was ran together in the program Autodimer to 
ensure that the primers did not interfere with one another or form hairpins upon 
themselves [62].  
Single base extension primers rs3114908 and rs6059655 were originally forward 
SBE primers. To allow these primers to work efficiently in the reaction these primers had 
to be switched to the reverse direction. Primer rs1126809 was flipped to the forward 
direction from its original reverse direction according to NCBI [59]. Primers rs12441727 
and rs10756819 had their “T” tail length adjusted to ensure that the SNPs fell in bins on 
the genetic analyzer in which they did not compete with other SNPs.  See Table 2 in 
Appendix A for table of SNP primers. The HIrisPlex and HIrisPlex-S protocols can be 
found in Tables 2 and 3 in Appendices B and C. 
Once the primer designs were finalized, concentrations were adjusted for each 
primer. This allowed for all peaks in the reaction to be easily visible without preferential 
amplification occurring. While all PCR-1 primers were kept at 0.4µm, each SBE primer 
was adjusted individually through singleplex and multiplex designs to find the ideal 
concentration for a clean profile to be produced at 1ng/µL. All trials were completed with 
control samples quantified at 1ng/µL to control for sample variation. This was all 
necessary for model validation and to push forth to publishing a biological assay for 
widespread use.  
To complete the developmental validation of this assay there are several tests that 
must be performed to state that the assay meets SWGDAM guidelines and is acceptable 
to be used in a forensic laboratory.  These guidelines include Sensitivity Study, Species 
Specificity, Mixture Assessment, Concordance Testing, Simulated Casework, Stability 
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Studies, and Population Studies. Of these Sensitivity Testing, Species Specificity, and 
Concordance Testing were completed in our laboratory.   
5.2.1 Sensitivity Testing  
Using a sample of control DNA as described in section 2.6, sensitivity testing was 
performed to determine the sensitivity range for the HIrisPlex-S assay. Based upon the 
results of this testing, the HIrisPlex-S system produces a full profile down to 60pg/µl of 
DNA. After 60pg/µl, dropout of SNPs rs12441727, rs3212355, and rs8051733 occur. 
This is illustrated in Figure 5.  
 
 
 
Figure 5 Electropherograms for Sensitivity for the HIrisPlex-S Capillary Electrophoresis 
Assay from 1ng/µl to 30pg/µl 
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5.2.2 Species Specificity 
After completing the sensitivity testing, species specificity testing was completed to 
ensure that the assay only produces complete profiles for human samples. Of the non-
human samples, there was no successful amplification in any of the electropherograms 
except for one peak in the chicken, one peak in the bovine, and several peaks in the 
primate. In the chimp, fourteen of the primers amplified and produced a partial profile. 
Due to the homology between the chimp and human genomes, this amplification was 
expected and acceptable. 
 
Figure 6 HIrisPlex-S Species Specificity 
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5.2.3 Concordance Casework Samples 
The final results obtained for the validation of the HIrisPlex-S system were the 
casework concordance results. This assessment ensures that this assay performs the exact 
same despite use on different machines and having different laboratory personnel setting 
up the assay. The results for this testing can be found in Table 14 located in Appendix N. 
Single source samples from a variety of sources such as blood, saliva, semen, touch DNA, 
vaginal secretions, and mucosa all produced clean profiles. Samples from dried blood, 
dried saliva, and touch DNA all resulted in clean electropherogram, but low peaks 
compare to the other single source samples. The same result was true for the blood 
sample with heme inhibition in that it produced a clean electropherogram with low peak 
heights. The analysis interpretation based upon the profile produced was consistent with 
the known phenotypic information for those samples. During the analysis of such 
samples, one touch DNA and one frozen blood sample had peak heights below the 
standard interpretation threshold and therefore a complete genotypic profile could not be 
obtained. Based upon these results, the phenotypic profile for these two samples could 
not be produced. Both samples had concentrations that were at or below the minimum 
input concentration of 60pg/µl for the assay.  
 Mixture profiles produced during this concordance set were observed to contain at 
least two or more individuals. Based upon this conclusion an interpretation of the results 
could not be made as mixture interpretation of SNP profiles on capillary electrophoresis 
is not possible since a major and minor contributor cannot be determined with SNPs as 
opposed to STRs.  
 Through this concordance testing only one sample produced an incorrect 
phenotypic profile. This sample was that of a mixture, but because the peak distribution 
due to degradation looked as though it were a single source sample it resulted in an 
incorrect prediction. This information along with all other concordance data is in Table 
14 in Appendix N.  
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CHAPTER 6. RESULTS AND DISCUSSION: HAIR 
MORPHOLOGY SNP AND GENE ASSOCIATION THROUGH 
MASSIVE PARALLEL NEXT GENERATION SEQUENCING 
91 SNPS were sequenced on the Illumina Miseq to determine the possible 
significance they may play in determining the type of hair structure an individual may 
exhibit. All 91 SNPs were amplified successfully with rs12130862, rs3001978, 
rs11575161, rs67587000, rs585583, rs2227311, and rs12913832 all being verified by 
manual reference. All SNPs for this assay can be found in Table 5 located in Appendix D.  
1026 samples were successfully sequenced at these 91 loci. 743 of these individuals 
were used in a study of 28,701 subjects from 9 cohorts of multiple geographic origins for 
multiple Genome Wide Association Studies [manuscript accepted].  
6.1 Development of a Custom MPS Assay 
The concept of Massive Parallel Sequencing, also known as Next Generation 
Sequencing, follows the same basic principles as Capillary Electrophoresis (CE) 
sequencing. In CE sequencing, DNA polymerase orchestrates the synthesis of millions of 
copies of a template DNA strand while incorporating fluorescently tagged dNTPs, 
dioxyribonucleotide triphosphates and ddNTPs (for chain termination). These florescent 
tags are identified by the genetic analyzer based upon their different wavelengths and 
therefore result in the sequence being read. MPS using cycling reversible termination 
allows for the overall concept to be the same, but hundreds of samples can be run 
simultaneously across millions of different DNA fragments instead of one individual 
sample at a time at one location.  
The custom protocol designed for the Illumina Miseq Next Generation Sequencer 
was based on a successful protocol developed in our laboratory with reference to Bronner 
et al. [27]. Each of the primers were designed to isolate between 100-300bp around the 
SNP of interest, much like a flanking primer. The same procedure was used as described 
in section 2.3 to design these Massive Parallel Sequencing primers. The only distinct 
difference with these types of primers is that the forward and reverse must have specific 
adapter sequences that allow the fragments or “amplicons” to adhere to the lawn found on 
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the Miseq flow cell. Owing to the increased number of SNPs for this reaction, it was 
difficult to have all the primers fall under an isolated temperature range concerning the 
melting temperature. Therefore, it became necessary to adapt the Miseq PCR 
amplification protocol to an appropriate type of PCR called a “touchdown PCR”. This 
type of PCR allows the cycle temperature to slowly decrease by 0.3ºC to ensure that the 
primers all bind and amplify appropriately based upon their specific temperature range 
during the annealing phase. In the case of this reaction it was necessary to extend the 
range from 57ºC to 64ºC. 
6.2 Development of a Custom Bead Clean Up Method  
Once the protocol for the Massive Parallel Next Generation Sequencing Assay was 
decided upon and the primers were successfully created, it was essential to develop a 
protocol for bead clean up that would rival that of the AmPure Bead cleanup but at a 
fraction of the cost. Bead cleanup is necessary over column cleanup to remove primer-
dimers and excess primers. To do this, it was necessary find the correct suspension of the 
PolyEthylene Glycol (PEG) (Fisher Scientific International Inc.) mixture with the Sera-
Mag Speed Beads (GE Healthcare, Waukesha, WI) to ensure that their specificity is only 
for the fragment sizes that needed removed, not affecting the 100 to 300 bp fragments, 
but removing the smaller fragments. After several trials at various concentrations of PEG, 
24% PEG with 5M NaCl seemed to be the most successful to provide the appropriate 
binding affinity for the beads to the DNA.  
To assess the beads to make sure that they operated proficiently for cleanup, a 
standard ladder was used as the cleanup sample. A dilution of the Fermentas Ultra Low 
Range Ladder (Fisher Scientific International Inc., Hampton, NH) to 10ng/µl was 
prepared. The standard bead cleanup protocol mentioned in section 3.5 was then used to 
clean up 2-4 duplicate ladder samples. Once the clean-up is achieved, the samples are 
then run on a 4% agarose gel at 120V for 60 minutes. The agar percentage was increased 
to 4% to help increase the resolution of the smaller band sizes. The bands should be 
visible between 100-300bp. A successful bead cleanup validation is displayed in Figure 7. 
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Figure 7 Successful Bead Preparation Validation with ratios of beads to sample of 1.0x to 
3.0x. 
6.3 Perfecting NGS Primers 
For the SNPs identified as essential to evaluating hair morphology, the designed 
primers were tested through two distinct methods to ensure that they worked successfully 
before applying them to a Miseq analysis. The first step to ensure the success of the 
primers, is to perform singleplex reactions, reactions in which only the primers of interest 
is used while water is substituted for the rest of the primers, and then ran through the 
standard first PCR protocol mentioned in section 3.5. This was done for all 91 primer sets. 
They were then ran on 4% agarose gel to see if a band of DNA was formed on the gel 
indicating successful amplification through the PCR with that specific primer.  
For any of the primers that did not successfully form a band (3 primers) on the 
agarose gel, the 2100 Agilent Bioanalyzer using the Agilent DNA 1000 Kit (Agilent, 
Santa Clara, CA) was used to also visualize as to whether the primer successfully 
amplified the DNA as intended or not. Primers rs30077681 and rs670741 did not amplify 
successfully the first time and were completely redesigned for successful amplification. 
Primer concentrations were adjusted based upon visibility of the banding on the gel (the 
lighter the bands mean the concentration needs increased) and on the Bioanalyzer.  
300bp 
Ladder empty   1.0x      1.5x       2.0x           2.5x         
3.0x 
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Once all of the primers were identified as successfully amplifying the regions of 
interest, they were multiplexed to one of three groups based upon the Autodimer results 
[62]. These groups were then verified on the Bioanalyzer as working well without 
inhibition of one another before being applied to the assay on the Miseq. This can be seen 
in Figure 8 below.  
 
Figure 8 Successful Group Multiplex for Miseq Assay on Bioanalyzer, peaks just after 40 
and 110 indicate standards. 
6.4 Sequence Alignment and Hair Structure Correlation Results 
All this assembly and conversion of the Miseq fastq files was performed on an 
iMac in a UNIX environment. To evaluate the data that was synthesized as a result of this 
Miseq run, a custom genome had to be assembled first to align the samples with. This 
custom genome allows for the isolation and alignment of the DNA to areas of interest as 
opposed to the whole genome, making evaluation of data a much simpler task. For the 
type of data that was produced, referred to as amplicons, aligning these to the entire 
genome would be error prone and memory intensive. Instead, by assembling a genome 
appropriate for this assay, we can ensure that the amplicons align exactly where intended. 
In sequencing our SNPs of interest, an area of about 400bp surrounding the SNPs of 
interest were isolated based upon sequence information provided by NCBI. From this 
data, a fasta file was created to which the Miseq sequencing data was aligned as 
described in section 3.5.  
 
In order to access the significance of the genotypic results ascertained from the 
Miseq hair structure assay, a Pearson’s correlation matrix was generated in R using the 
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Corr and pcorr test from the Psych package [63]. Each SNPs correlation was tested 
against the hair structure type identified by the participants. This correlation was ran both 
with and without correcting for age and sex. All SNPs of significance were seen in both 
correlation, the matrices are located in Tables 13 and 14 in Appendices O and P. A 
Bonferroni correction was performed due to the nature of the multiple testing present for 
the 91 SNPs the p-value was adjusted to 0.000549. 14 SNPs were found to be significant 
in both the corrected and uncorrected correlation based upon the adjusted p-value.  These 
14 SNPs were rs1150606, rs11568820, rs11803731, rs12913832, rs17646946, rs310642, 
rs3827760, rs4672907, rs4845418, rs5919324, rs80293268, rs95365032, rs2219783, and 
rs9568036.  
The correlations for rs1150606, rs11568820, rs11803731, rs12913832, rs17646946, 
rs310642, rs3827760, rs4672907, rs4845418, rs5919324, rs80293268, and rs95365032 
were not mirrored in the Meta-Analysis study as significant. This difference in 
significance can largely be attributed to the vast difference in sample size as our study 
only had 1026 individuals (reduced power) while the meta-analysis had 28,701 
individuals. The composition of our samples may also contribute to this variation in 
significance as 743 of these samples were strictly from European populations by design.  
6.5 Correlation in Conjunction with Meta-Analysis Collaboration 
While twelve of the SNPs found to be significant in the Pearson correlation 
performed in our assay did not reach significance in the meta-analyses, SNPs rs2219783, 
rs310642 and rs80293268 were deemed significant in both our correlations and the Meta 
Analysis [manuscript accepted].  
Intronic variant, rs2219783, is located in the LGR4 gene. LGR4 triggers the Wnt 
signaling pathway via G-protein couple receptors, this is known to control hair growth 
and structure. This gene been shown in knockout mice to reduce the effects of EDAR, 
LEF1, and SHH. These three genes are all required for hair follicle development and thus 
it would be logical for this SNP to possibly help control the structure of the hair [40].  
Intronic variant, rs310642, located in PTK6 encodes protein tyrosine kinase, which 
functions in epithelial cells as an intracellular signal transducer [52]. After inspecting the 
data obtained for all individuals at this SNP, the genotype of homozygous minor allele 
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(CC) seems to lend an association with a curly haired phenotype. Further investigation 
needs to be conducted to determine the significance of this SNP in relation to hair 
morphology. 
The SNP rs80293268 was found to be significant and is located intergenic of 
ERRFI1 and SLC45A1. ERRFI1, also known as RALT, encodes an inhibitor of epidermal 
growth factor receptor. This is essential in hair follicle development along with 
homeostasis of the epidermis [52, 53]. An overexpression of RALT has also been 
identified in mice to result in a wave phenotype, which is consistent with a wavy coat and 
curly whiskers as well [64].  After the assessment of this SNP for all individuals in our 
dataset, the genotype of homozygous minor allele (CC) seems to lend an association with 
a straight-haired phenotype. Further investigation needs to be conducted to determine the 
significance of this SNP in relation to hair morphology. 
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CHAPTER 7. RESULTS AND DISCUSSION: MIGRATING 
HIRISPLEX- S TO THE MASSIVE PARALLEL NEXT 
GENERATION SEQUENCING PLATFORM 
7.1 InnoQuant for Validation Sample Concentration   
The InnoQuant Human DNA Quantification and Degradation Assessment Kit was 
used to assess the quality of the validation samples for the Miseq HIrisPlex-S assay. 
Before running the actual samples, DNA standards ranging from 0.009 ng/µl to 20ng/µl 
were ran to insure proper calibration of the system. Based off the calibration, the 
instrument was set up to run the InnoQuant assay. Five point standards were run along 
with the validation samples [58].  This is to ensure proper function of the assay. DNA 
standard at 100ng/µL was provided with the assay and was diluted using InnoQuant 
Dilution Buffer A to make the five point standards. These standards range from 
0.005ng/µL to 20 ng/µL.  Prior to running, the instrument was calibrated for the dyes: 
Cy5, Cy3, and ROX. 
The validation samples were diluted to 1ng/µL, based on concentrations previously 
determined using Qubit dsDNA HS assay, to assess for correct concentration and 
degradation using InnoQuant assay. To run the validation samples a master mix 
containing 10µl of Agilent Brilliant Multiplex QPCR Master Mix, 0.3µL Agilent 
Reference Dye, and 7.7µL InnoQuant Primer Mix was made. 2µl of sample or standard 
was added to the well initially, followed by 18µl of the master mix.  The InnoQuant H-
dye HID Run Template_v1.0 was used to set up the appropriate PCR run conditions, dye 
configurations, and standard curve replicates. The cycling parameters specified were an 
initial heating time of 10 minutes at 95ᴼC, followed by 32 cycles of 15 seconds at 95ᴼC 
then 2 minutes at 61ᴼC [58].   
Once the run was complete, the R2 and efficiency values were evaluated to ensure 
that the run was successful.  For a successful run, the reference values for these runs were 
required to have R2 > 0.98 and the efficiency values have a passing range of greater than 
90%, but less than 110%. The validation samples were ran in two separate runs. The first 
run contained non-casework validation samples. The long read R2 value was 0.987 and 
the efficiency percentage was 109.579. The short read for non-casework validation 
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samples R2 value was 0.993 and the efficiency percentage was 108.478. For the casework 
validation samples, the long read R2 value was 0.999 and the efficiency percentage was 
106.54. For the short read R2 value was 0.998 and the efficiency percentage was 94.119.  
Based upon the concentrations determined through the InnoQuant assay, the 
samples’ original concentrations were determined and the validation samples were 
diluted to the target concentration. Three of these samples were then spot checked 
through InnoQuant.  
7.2 SBE Product Formation 
After visualizing the primer bands, it was necessary to multiplex the primers to 
determine if any of the primers inhibited one another. It was also decided that a standard 
ExoProStar clean up would be performed on these multiplexed samples and then, using 
the already established SBE primers for the HIrisPlex and HIrisPlex-S, a standard SBE 
reaction and SAP cleanup were performed. The concentrations used for these SBE 
primers were used as though following the standard HIrisPlex-S assay found in Tables 2 
and 3 in Appendices B and C. While SBE primers are not at all necessary for NGS, 
performing this check on the NGS primers allowed for the amplification of the SNP of 
interest to be observed, therefore ensuring that the primer would anneal and amplify 
appropriately. All reactions were performed on the same sample at a concentration of 2 
ng/µL to take away the variability of concentration change in a variety of samples.  
7.3 Singleplex to Standardize Coverage 
To continue forth in creating a biological assay that can be used on a widespread 
scale and to avoid preferential amplification of fragments, the next step was to 
standardize the amplification coverage of each primer on one control DNA sample as 
mentioned above to standardize initial concentration. To do this, concentrations were 
adjusted based upon the band results from section 4.3. The standard PCR protocol used 
for this assay mentioned in section 4.3 was performed and then rather than running the 
sample on a gel, the samples were ran on the Qubit to determine the quantity of product 
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produced prior to clean up. The goal concentration was +/- 5ng/µL of 28 ng/µL for that 
sample. Several trials of adjustments were made to get these primers into that range.  
7.4 Optimizing PCR Conditions and Primer Concentrations 
After completing a successful Miseq run to observe the performance of the primers 
to determine optimal concentrations, it became apparent that it was necessary to adjust 
our PCR. Based upon the analysis from this first run, it was apparent that the primers 
were not extending as they should be, possibly due to the PCR settings. It was at this 
point the cycling parameters were adjusted to an initial heating time of 10 minutes at 
95ᴼC, followed by 34 cycles of 30 seconds at 95ᴼC then touchdown at 62°C decreasing 
by 0.3 for 30 seconds and then 60ᴼC for 10s, finally 5 minutes at 60°C.   
Due to the possibility of SNP dropout and preferential amplification, it was 
necessary to analyze the coverage once the reaction had been deemed successful in that 
the primers function appropriately. An analytical threshold of 100x coverage was set as 
our parameter for determining whether a primer’s concentration needed to be adjusted. 
Primers for SNPs rs12821256, rs683, rs1800414, and rs1470608 all had coverage below 
100 reads, but above 50 read. This allowed us to determine that the primer had worked 
successfully, but the concentration needed to be increased to meet our coverage threshold.  
Primers for SNPs rs6119471 and rs1545397 however did not produce reads anywhere 
near our necessary minimum and at this point it was necessary to redesign the primers 
again to allow for the minimum coverage to be achieved. Besides the previously 
mentioned six primers, all the remaining primers performed at coverages significantly 
higher than the analytical threshold set forth. Based upon this observation it would be 
necessary to increase the concentration of the underperforming primers while decreasing 
the concentration of those performing at a much higher coverage.   
The lack of coverage for rs1545397 was remedied by redesigning the forward 
primer while keeping the previously designed reverse primer. This resolved the lack of 
coverage at this SNP. The lack of coverage present on rs6119471 was remedied by 
redesign of the forward primer and reducing the overall fragment size (including adapters) 
to a much smaller size of 128bp from the previous size of 225bp.  
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Singleplex runs of each primer were performed at 0.5µm for the MC1R set 
primers and 0.4 µm for the remaining primers. The appropriate PCR method was 
determined to be a touchdown PCR with a temperature range of 57˚C to 62˚C with a 
0.3ºC interval decrease to optimize the annealing of the primers for product formation. At 
this point the product was then not cleaned up, but rather ran on a 4% agarose gel to 
determine if band formation occurred indicating product formation as well as if the 
product appeared to be the appropriate size.  
7.5 Perfecting the Bead Cleanup Protocol 
 To make the current bead protocol in place work successfully for the Miseq 
HIrisPlex-S assay it was essential to determine the ratio of beads to sample that 
successfully remove excess primers so that the sequencing can be focused on just the 
amplicons we have isolated for sequencing. The ratios and the subsequent size fragments 
that can be removed can be found in the table below.  
 
Table 1 Sample to Bead Ratio for Bead Cleanup 
Sample 
to 
Beads 
Ratio 
Example 
of 
Sample 
to Beads 
Ratio 
Size 
Selection 
Comments 
 
Bioanalyzer Electropherogram 
Profile 
Bioanalyzer 
Gel profile 
1: 0.8 20uL: 
16uL 
Removes 
everything 
less than 
200bp; 
Only 200bp 
and 300bp 
bands are 
visible on 
bioanalyzer 
with a faint 
band for 
150bp 
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Table 1 continued 
 
 
 
 
1:1 20uL: 
20uL 
Removes 
everything 
less than 
150bp; 
Only three 
bands – 
150, 200 
and 300bp 
are visible. 
 
 
1:1.25 20uL: 
25uL 
Removes 
everything 
less than 
100bp; Four 
bands- 
100,150,20
0 and 
300bp are 
visible 
 
 
1:1.5 20uL: 
30uL 
Removes 
everything 
less than 
75bp; Five 
bands are 
visible-
75,100,150,
200 and 
300bp; 
75bp is not 
very strong 
 
 
1:1.8 20uL: 
36uL 
Five strong 
bands: 75-
300bp;50bp 
starts to 
show up  
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Table 1 continued 
 
1:2 20uL: 
40uL 
Five strong 
bands: 75-
300bp; 
50bp shows 
up as well 
 
 
 
For this assay fragments under 100bp needed to be removed so a cleanup in the ratio of 
1:1.25 is necessary to successfully clean up the reaction to be ran on the Miseq. The 
standard protocol developed in section 3.3 was then followed as stated. 
7.6 Finalized Protocol for HIrisPlex-S Massive Parallel Next Generation Sequencing 
Assay 
The coverage and sensitivity assessment of the optimization run are ongoing but 
current run results can be found in Table 17 located in Appendix R. Through this run we 
could determine the successful amplification of all areas of interest and perform an 
assessment of the coverage at each SNP. Based upon this coverage assessment, 
concentrations will be adjusted and optimized to produce and efficient Forensic DNA 
Phenotyping tool for the Illumina Miseq. Once final optimization of the concentrations is 
made validation plates will be ran and assessed.  
Depth of coverage was assessed for samples whose concentration was 
approximately 500pg. Each SNP was individually analyzed for read depth and average 
coverage across all the 500pg samples were obtained. Based on the analysis, 10 SNPs had 
coverage < 100x, whereas certain SNPs had greater depth of coverage. The SNPs that had 
<100x coverage are rs1805009, rs12821256, rs12203592, rs2402130, rs12913832, rs683, 
rs2238289, rs17128291, rs1470608 and rs1426654. Whereas the SNPs that had greater 
depth of coverage were rs6119471- 35667x, rs1545397- 4078x, rs10756819- 1254x and 
rs8051733- 1190x. Further optimization needs to be performed on these SNPs in order to 
balance the reaction such that there is no preferential amplification during the multiplex 
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PCR reaction. Ensuring the depth of coverage is uniform on an average reduces the 
possibility of SNP drop out for low concentration or degraded samples. For example, the 
primer concentration for each of the low coverage SNPs would be increased and the 
primer concentration for each of the greater coverage SNPs would be decreased to bring a 
balance in the PCR amplification process. The standard deviation for each of the SNPs 
across all the 500pg samples is very high and this could be attributed to the variance in 
quality of the samples and concentration that comes along with an in-house validation set.  
This issue can be alleviated by optimizing the coverage using stable control DNAs (9948, 
9947A and 007) at various range of concentrations to achieve the desired coverage. These 
results can be found in Table 17 in Appendix R. 
7.7 Casework Assessment  
Depth of coverage was assessed for two saliva casework samples, one that was 
fresh and one that was degraded. Each SNP was individually analyzed for read depth 
across both samples. Based on the analysis, 34 SNPs for the non-degraded saliva 
casework sample had coverage > 100x, whereas certain SNPs had greater depth of 
coverage. The SNPs that had >100x coverage are rs312262906, rs11547564, rs885479, 
rs1805008, rs1805005, rs1805006, rs1805007, rs201326893, rs2228479, rs1110400, 
rs28777, rs16891982, rs4959270, rs1042602, rs1800407, rs2402130, rs2378249, 
rs128963999, rs1393350, rs3114908, rs1800414, rs10756819, rs17128291, rs6497292, 
rs1129038, rs1667394, rs1129038, rs1470608, rs6119471, rs1545397, 6059655, 
rs12441727, rs3212355, and rs8051733. Whereas the SNPs that had greater depth of 
coverage were rs6119471- 33315x, rs1545397- 7994x, rs10756819- 1429x and 
rs8051733- 3962x. However, for the degraded samples, 25 had a coverage >100x, 
rs312262906, rs11547564, rs885479, rs1805008, rs1805005, rs1805006, rs1805007, 
rs201326893, rs2228479, rs1110400, rs16891982, rs4959270, rs1042602, rs2378249, 
rs128963999, rs1393350, rs3114908, rs10756819, rs6497292, rs1667394, rs6119471, 
rs1545397, 6059655, rs12441727, and rs8051733. SNP rs1805009 dropped out in the 
degraded analysis. Further optimization needs to be performed on these SNPs to balance 
the reaction such that there is no preferential amplification during the multiplex PCR 
reaction. Ensuring the depth of coverage is uniform on an average, reduces the possibility 
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of SNP drop out for low concentration or degraded samples.  For example, the primer 
concentration for each of the low coverage SNPs would be increased and the primer 
concentration for each of the greater coverage SNPs would be decreased to bring a 
balance in the PCR amplification process. While primer adjustment does need to take 
place, the overall outcome of the casework sample displayed the same decrease in 
coverage for the degraded sample, but still exhibited coverage over our interpretative 
threshold. More casework samples will need to be ran and examined during the validation 
to ensure adequate performance on these types of samples.  
7.8 Mixture Assessment 
A large problem in the forensic science field today involves the deconvolution of 
mixtures. Majority of forensic samples that come into laboratories are mixture samples 
and identifying the contributors could lead to a much higher rate of solving these crimes. 
Through the design and development of the HIrisPlex-S MPS assay we have identified a 
possibility that indeed MPS technologies may be able to help solve this problem.  
For our validation plate, we ran mixture profiles of two individuals in ratios of 1:1, 
1:2, 1:5, and 1:10. The goal behind this was two-fold, in that we wanted to see if we 
could separate the mixture by individuals with different phenotypes and well as with 
individuals with like phenotypes. What we observed upon analyzing these profiles is that 
we may be able to pull apart individuals of different phenotypic characteristics. Below 
are two examples of mixtures that were analyzed to see if successful separation of 
individual profiles could be achieved. Both exemplar mixtures below are in 5ng:500pg 
ratios.  In both mixtures, the pigmentation SNP of interest was identified first. Once this 
SNP was identified, variation in neighboring SNPs to the pigmentation SNP were also 
identified. We aimed to identify two or more neighboring SNPs to ensure accuracy of 
observation. A close investigation of SNPs in the adjacent regions of HPS SNPs, led to 
the identification of unique patterns in neighboring SNPs, allowing for us to identify 
individual contributors rather than just heterozygous loci. To also rule out heterozygosity, 
we looked at the coverage of both the pigmentation SNP as well as the neighboring SNPs. 
In all the 5ng:500pg mixtures, the coverage was in a 1:10 ratio of minor to major 
contributor therefore reinforcing the identification of individual contributors.  
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Figure 9 Two 5ng:500pg Mixture Deconvolutions 
 
While this does provide us with an interesting possibility the mixtures can be pulled 
apart through this method, much more research must be done to determine how to 
effectively complete this task. To increase the accuracy of this deconvolution, including 
more neighboring SNPs in the regions of interest may prove useful. This could be 
successfully achieved through intentionally including more neighboring SNPs in primer 
design. Having multiple SNPs in one region of interest would potentially increase the 
likelihood that a pattern in genotypes could be observed, allowing for an individual to be 
pinpointed for each sequence strand of DNA. Observation at various mixture ratios also 
needs to be analyzed to determine the success of this technique at all ratios. While we do 
believe that the separation of these mixtures is possible, more analyses and research is 
needed to be able to fully assess the success rate of mixture deconvolution.  
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7.9 Comparison of Capillary Electrophoresis against the Miseq for HPS Genotyping 
One of the key motivating factors behind developing this HIrisPlex-S 
assay on the Next Generation Sequencing platform, in addition to the vast amount of 
information these assays provide is to reduce the time and cost of performing these 
predictions to allow these to be more applicable to the forensic science field. To 
determine the cost efficiency of these assays it was necessary to compare the cost of the 
two methods when running the same amount of predictions on the same number of 
samples. The table for 384 samples can be found in Table 18 located in Appendix S. 
For 384 samples, the cost to run the samples on the Capillary Electrophoresis, the 
cost came to about $4495; whereas running 384 samples on the Miseq, costs about $2911. 
A capillary electrophoresis based HIrisPlex-S run for 384 samples takes about 95 hours 
in total to run from the Flanking PCR step all the way through the genotyping. However, 
for a Miseq run for 384 samples it only takes about 45 hours. As illustrated, the Miseq 
reduces not only the cost of the run, but also the run set up time by approximately half. 
Therefore, this illustrates that running 384 samples on the Miseq is half of the cost and 
the amount of time that it would take to run the same number of sample predictions on 
the Genetic Analyzer, thus supporting the idea that the implementation of this in forensic 
laboratories would not only provide more information to law enforcement, but also save 
time and money when doing so.  
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CHAPTER 8. CONCLUSIONS 
The first goal of this research was to assist in generating a skin color prediction 
model and in addition develop and validate the HIrisPlex-S assay for the prediction of 
eye, hair, and skin color from DNA. 329 individual samples from our laboratory were 
successfully used in model generation to increase the geographic distribution of the 
dataset therefore allowing us to obtain a globally accurate skin color prediction tool. 194 
model test subjects were used to compare our 41-SNP prediction model to the Snipper 
model set forth by Maronas et al. [3]. This comparison allowed us to demonstrate that our 
five-category skin pigmentation tool did not only produce more accurate predictions, but 
also allowed our model to illustrate its ability to predict skin color independently of 
biogeographical ancestry.  We could successfully produce a multiplex assay that targeted 
17 skin color predictive SNPs to be used in conjunction with the 24 SNPs identified for 
the HIrisPlex assay allowing a full profile to be produce through of free online web-based 
tool. This assay can produce a full 41-SNP profile to with a minimum DNA input value 
of 63pg. This human-specific assay generates probabilities for 3 eye colors, 4 hair colors, 
and 5 skin color categories. From this point, research into further physical appearance 
characteristics is necessary to improve prediction accuracy and add new phenotypic traits. 
This is especially true when looking at “intermediate” eye color and pale-very pale skin 
pigmentation as these are areas where more accurate predictions must be worked towards.  
The second goal of this research was to develop a MPS assay that migrates the 
HIrisPlex-S assay from the Capillary Electrophoresis to the Illumina Miseq. This assay 
develops the 41 SNP profile through sequencing by synthesis. While optimization is 
ongoing, possible differentiation in sources of mixture profiles has been observed in 
addition to complete sample profiles. Further optimization including adjusting primer 
concentrations is necessary to further develop this assay. Once optimization is finalized 
the developmental validation data must be generated for assessment. This assessment will 
allow the parameters and success of the assay to be determined. Further research 
following optimization is necessary for the addition of new physical appearance traits 
along with the ability of this assay to discern mixture samples. 
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The final goal of this research was to develop a MPS assay that generated data to 
assess the correlation of 91 different SNPs with categorical hair morphology.  1026 
samples were genotyped in our laboratory and assessed at these 91 SNPs of interest. 
From our data set we could identify a possible correlation between the SNPs rs2219783, 
rs310642, and rs80293268. We could observe a possible association between the straight-
haired phenotype and the homozygous minor allele (CC) for rs80293268 as well as a 
possible association between the curly haired phenotype and the homozygous minor 
allele (CC) for rs310642. Further research and functional animal and human studies into 
these SNPs, is essential in conclusively identifying the role these genetic variants play in 
hair morphology. 
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APPENDIX A 
Table 2 SNPs for HIrisPlex-S 
 
 
Gene SNP Chromosome 
Location 
GRCh38.p7
Major 
Allele
Minor 
Allele
PCR Primer Flanking Forward Primer Flanking Reverse Primer 
Product 
Size(bp)
Reference 
MC1R N29insA(rs312262906) 16 89919341
A 
insertion
- MC1Rset1
TCGTCGGCAGCGTCAGATGTGTATAAGA
GACAGGCAGGGATCCCAGAGAAGAC
GTCTCGTGGGCTCGGAGATGTGTATAAG
AGACAGTCAGAGATGGACACCTCCAG
117 Branicki et al. , Pospiech et al. , Grimes et al. 
MC1R rs2228479 16 89919531 G A
Branicki et al.  , Pospiech et al.  , Grimes et al ., 
Strum et al.  
MC1R rs1805005 16 89919435 G T
Branicki et al.  , Pospiech et al.  , Grimes et al ., 
Strum et al.  
MC1R rs1805006 16 89919509 C A
Branicki et al.  , Pospiech et al.  , Grimes et al ., 
Strum et al.  
MC1R rs11547464 16 89919682 G A
Branicki et al. , Pospiech et al. , Grimes et al ., 
Strum et al.  
MC1R rs885479 16 89919745 G A
Branicki et al. , Pospiech et al. , Grimes et al ., 
Strum et al.  
MC1R rs1805007 16 89919708 C T
Branicki et al.  , Valenzuela et al.  , Strum et 
al. , Sulem et al.  , Duffy et al. 
MC1R rs1805008 16 89919735 C T Branicki et al. , Hart et al. , Strum et al. 
MC1R
Y152OCH 
(rs201326893)
16 89919713 C A Pospiech et al . , Grimes et al. 
MC1R rs1110400 16 89919721 T C Branicki et al. , Pospiech et al. , Grimes et al. 
MC1R rs1805009 16 89920137 G C MC1Rset4
TCGTCGGCAGCGTCAGATGTGTATAAGA
GACAGCAAGAACTTCAACCTCTTTCTCG
GTCTCGTGGGCTCGGAGATGTGTATAAG
AGACAGCACCTCCTTGAGCGTCCTG
106 Branicki et al. , Pospiech et al. , Grimes et al. 
SLC45A2 rs28777 5 33958853 C A
TCGTCGGCAGCGTCAGATGTGTATAAGA
GACAGTACTCGTGTGGGAGTTCCAT
GTCTCGTGGGCTCGGAGATGTGTATAAG
AGACAGTCTTTGATGTCCCCTTCGAT
150 Han et al . , Pospiech et al . 
SLC45A2 rs16891982 5 33951587 C G
TCGTCGGCAGCGTCAGATGTGTATAAGA
GACAGTCCAAGTTGTGCTAGACCAGA
GTCTCGTGGGCTCGGAGATGTGTATAAG
AGACAGCGAAAGAGGAGTCGAGGTTG
128
Lui et al ., Valenzuela et al ., Branicki et al . , 
Pospiech et al . , Grimes et al . 
KITLG rs12821256 12 88934557 T C
TCGTCGGCAGCGTCAGATGTGTATAAGA
GACAGATGCCCAAAGGATAAGGAAT
GTCTCGTGGGCTCGGAGATGTGTATAAG
AGACAGGGAGCCAAGGGCATGTTACT
118
Sulem et al. , Branicki et al.  , Pospiech et al.  , 
Han et al.
EXOC2 rs4959270 6 457747 C A
TCGTCGGCAGCGTCAGATGTGTATAAGA
GACAGTgagaaatctacccccacga
GTCTCGTGGGCTCGGAGATGTGTATAAG
AGACAGGTGTTCTTACCCCCTGTGGA
140 Sulem et al. , Branicki et al.  , Han et al.
IRF4 rs12203592 6 396320 C T rs12203592
TCGTCGGCAGCGTCAGATGTGTATAAGA
GACAGAGGGCAGCTGATCTCTTCAG
GTCTCGTGGGCTCGGAGATGTGTATAAG
AGACAGGCTTCGTCATATGGCTAAACCT
126
Sulem et al. , Branicki et al.  , Han et al. , Liu et 
al.
TYR rs1042602 11 89178527 C A rs1042602
TCGTCGGCAGCGTCAGATGTGTATAAGA
GACAGCAACACCCATGTTTAACGACA
GTCTCGTGGGCTCGGAGATGTGTATAAG
AGACAGGCTTCATGGGCAAAATCAAT
124 Stokowski et al. ,  Pospiech et al. 
OCA2 rs1800407 15 27985171 G A rs1800407
TCGTCGGCAGCGTCAGATGTGTATAAGA
GACAGAAGGCTGCCTCTGTTCTACG
GTCTCGTGGGCTCGGAGATGTGTATAAG
AGACAGCGATGAGACAGAGCATGATGA
124
 Branicki et al.  , Pospiech et al.,  Liu et al., 
Frudakis et al., Duffy et al.
SLC24A4 rs2402130 14 92334858 G A rs2402130
TCGTCGGCAGCGTCAGATGTGTATAAGA
GACAGacctgtctcacagtgctgct
GTCTCGTGGGCTCGGAGATGTGTATAAG
AGACAGTTCACCTCgatgacgatgat
150 Sulem et al. , Branicki et al. , Pospiech et al. 
HERC2 rs12913832 15 28120471 A G rs12913832
TCGTCGGCAGCGTCAGATGTGTATAAGA
GACAGTCAACATCAGGGTAAAAATCATG
T
GTCTCGTGGGCTCGGAGATGTGTATAAG
AGACAGGGCCCCTGATGATGATAGC
150
Lui et al ., Valenzuela et al ., Branicki et al . 
,Strum et al .  Sulem et al. , Duffy et al.
PIGU rs2378249 20 34630285 A G rs2378249
TCGTCGGCAGCGTCAGATGTGTATAAGA
GACAGCGCATAACCCATCCCTCTAA
GTCTCGTGGGCTCGGAGATGTGTATAAG
AGACAGCATTGCTTTTCAGCCCACAC
136 Branicki et al. 
SLC24A4 rs12896399 14 92307318 G T rs12896399
TCGTCGGCAGCGTCAGATGTGTATAAGA
GACAGCTGGCGATCCAATTCTTTGT
GTCTCGTGGGCTCGGAGATGTGTATAAG
AGACAGGACCCTGTGTGAGACCCAGT
125 Lui et al. , Han et al. , Sulem et al.
TYR rs1393350 11 89277877 G A rs1393350
TCGTCGGCAGCGTCAGATGTGTATAAGA
GACAGTTTCTTTATCCCCCTGATGC
GTCTCGTGGGCTCGGAGATGTGTATAAG
AGACAGGGGAAGGTGAATGATAACACG
124 Branicki et al. , Han et al., Liu et al.
TRYP1 rs683 9 12709304 A C rs683
TCGTCGGCAGCGTCAGATGTGTATAAGA
GACAGCACAAAACCACCTGGTTGAA
GTCTCGTGGGCTCGGAGATGTGTATAAG
AGACAGTGAAAGGGTCTTCCCAGCTT
138  Branicki et al.  Liu et al., Frudakis et al.
ANKRD11 rs3114908 16 89317316 G A rs3114908
TCGTCGGCAGCGTCAGATGTGTATAAGA
GACAGCAGAACACAGCCACACCCTA
GTCTCGTGGGCTCGGAGATGTGTATAAG
AGACAGCATAAAGGGGTCACCAGCAA
99 Law et al.
OCA2 rs1800414 15 27951890 A G rs1800414
TCGTCGGCAGCGTCAGATGTGTATAAGA
GACAGGCTGCAGGAGTCAGAAGGTT
GTCTCGTGGGCTCGGAGATGTGTATAAG
AGACAGGGGACAAACGAATTGAGGAA
197 Edwards et al.  Lao et al., Soejima et al.
BNC2 rs10756819 9 16858085 G A rs10756819
TCGTCGGCAGCGTCAGATGTGTATAAGA
GACAGAAAGCAAGCTCATGTTTCCA
GTCTCGTGGGCTCGGAGATGTGTATAAG
AGACAGCGTCATGACTAGAAAAACACC
AA
145 Liu et al., Visser et al. 
HERC2 rs2238289 15 28208068 T C rs2238289
TCGTCGGCAGCGTCAGATGTGTATAAGA
GACAGGGAACATGAAGATTTCCCAGT
GTCTCGTGGGCTCGGAGATGTGTATAAG
AGACAGCTGATTCAGGTCTGCTGTCACT
112 Mengel-form et al.
SLC24A4 rs17128291 14 92416481 A G rs17128291
TCGTCGGCAGCGTCAGATGTGTATAAGA
GACAGCCAGCACTGCCAAAATAACA
GTCTCGTGGGCTCGGAGATGTGTATAAG
AGACAGCTCTTTGGACCCATCACCTC
129 Liu et al.
HERC2 rs6497292 15 28251048 G A rs6497292
TCGTCGGCAGCGTCAGATGTGTATAAGA
GACAGTCTGCTGTAGAACCAATGTCC
GTCTCGTGGGCTCGGAGATGTGTATAAG
AGACAGGAATTGCACCTGTAGCTCCAT
150 Liu et al.
HERC2 rs1129038 15 28111712 G A rs1129038
TCGTCGGCAGCGTCAGATGTGTATAAGA
GACAGATGTCGACTCCTTTGCTTCG
GTCTCGTGGGCTCGGAGATGTGTATAAG
AGACAGACACCAGGCAGCCTACAGTC
137 Mengel-form et al. , Shekar et al. , Liu et al . 
HERC2 rs1667394 15 28285035 G A rs1667394
TCGTCGGCAGCGTCAGATGTGTATAAGA
GACAGCAGCTGTAGAGAGAGACTTTGAG
G
GTCTCGTGGGCTCGGAGATGTGTATAAG
AGACAGCACCATTAAGACGCAGCAAT
117
Sulem et al. , Eriksson et al.  Duffy et al. , Liu 
et al. 
MC1R rs1126809 16 89919713 G A rs1126809
TCGTCGGCAGCGTCAGATGTGTATAAGA
GACAGTGTTTCTTAGTCTGAATAACCTTTT
CC
GTCTCGTGGGCTCGGAGATGTGTATAAG
AGACAGGGTGCATTGGCTTCTGGATA
100 Branicki et al. 
OCA2 rs1470608 15 28042974 A C rs1470608
TCGTCGGCAGCGTCAGATGTGTATAAGA
GACAGTTTCTTGTGTTAACTGTCCTTACAA
A
GTCTCGTGGGCTCGGAGATGTGTATAAG
AGACAGGGAAAATATGTTAGGGTTGATG
G
218
Norton et al. , Valenzuela et al. , Stokowski et 
al., Branicki et al.
SLC24A5 rs1426654 15 48134286 G A rs1426654
TCGTCGGCAGCGTCAGATGTGTATAAGA
GACAGTTCAGCCCTTGGATTGTCTC
GTCTCGTGGGCTCGGAGATGTGTATAAG
AGACAGTGAGTAAGCAAGAAGTATAAG
GAGCA
212 Hart et al. , Maronas et al., Stokowski et al. 
ASIP rs6119471 20 34197405 C G rs6119471
TCGTCGGCAGCGTCAGATGTGTATAAGA
GACAGGCAGGAGAATTGCTGGAACT
GTCTCGTGGGCTCGGAGATGTGTATAAG
AGACAGAACCCGAAGGAAGAGTGAAAA
174 Frudakis et al. , Hart et al.
OCA2 rs1545397 15 27942625 A T rs1545397
TCGTCGGCAGCGTCAGATGTGTATAAGA
GACAGGGTATAGGATTATTTGGGGAATG
A
GTCTCGTGGGCTCGGAGATGTGTATAAG
AGACAGTGGAGATATAGAATTCACACAA
CATAAA
144 Edwards et al. 
RALY rs6059655 20 34077941 G A rs6059655
TCGTCGGCAGCGTCAGATGTGTATAAGA
GACAGGTGAGGAAATCGAGGCTCAG
GTCTCGTGGGCTCGGAGATGTGTATAAG
AGACAGAGGAGAAAGCTGCAGATCCA
112 Jacobs et al.  
OCA2 rs12441727 15 28026628 G A rs12441727
TCGTCGGCAGCGTCAGATGTGTATAAGA
GACAGGGGAAGAGACAGCTCCATGT
GTCTCGTGGGCTCGGAGATGTGTATAAG
AGACAGACAATCCTGGGAGGTACACG
137 Liu et al.
MC1R rs3212355 16 89917969 C T rs3212355
TCGTCGGCAGCGTCAGATGTGTATAAGA
GACAGGAGTGAACCCAGGAAGATGC
GTCTCGTGGGCTCGGAGATGTGTATAAG
AGACAGCATCAAAGGCAGACCTCTCG
199 Valenzuela et al. 
DEF8 rs8051733 16 89957797 G A rs8051733
TCGTCGGCAGCGTCAGATGTGTATAAGA
GACAGAGGCGGTGGTCTCTCTCTC
GTCTCGTGGGCTCGGAGATGTGTATAAG
AGACAGTTGCAACAGGAGGGTCTAGG
124 Law et al.
MC1Rset2
TCGTCGGCAGCGTCAGATGTGTATAAGA
GACAGGTCCAGCCTCTGCTTCCTG
GTCTCGTGGGCTCGGAGATGTGTATAAG
AGACAGAGCGTGCTGAAGACGACAC
MC1Rset3
TCGTCGGCAGCGTCAGATGTGTATAAGA
GACAGCTGGTGAGCTTGGTGGAGA
GTCTCGTGGGCTCGGAGATGTGTATAAG
AGACAGTCCAGCAGGAGGATGACG
147
158
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APPENDIX B 
Table 3 HIrisPlex Protocol for HIrisPlex-S 
 
 
 
 
 
 
 
 
 
 
 
No. SNP Primer set PCR Ps d STOCK(50um) 35 Dir SNPs Conc p of 10um(ul) of 20um(ul) of 50um(ul) 35
1 N29insA_(DU)snF MC1Rset1 (1F&R) 0.1 each F&R =0.5um 3.5 1F C/A 1.3um 0.13 4.55
2 rs11547464_(H)snF MC1Rset3 (3F&R) 0.1 each F&R =0.5um 3.5 2F G/A 0.1 um 0.05 1.75
3 rs885479_(BD)snR MC1Rset3 3R C/T 1.25um 0.125 4.375
4 rs1805008_(FU)snF MC1Rset3 4F C/T 0.375um 0.0375 1.3125
5 rs1805005_(FU)snF MC1Rset2 (2F&R) 0.1 each F&R =0.5um 3.5 5F G/T 1um 0.1 3.5
6 rs1805006_(FU)snF MC1Rset2 6F C/A 0.8um 0.08 2.8
7 rs1805007_(T)snF MC1Rset3 7F C/T 1.1um 0.11 3.85
8 rs1805009_(T)snF MC1Rset4 (4F&R) 0.08 each F&R =0.4um 2.8 8F G/C 0.12um 0.03 1.05
9 Y152OCH_(FU)snF MC1Rset3 9F C/A 0.5um 0.05 1.75
10 rs2228479_(T)snF MC1Rset2 10F G/A 0.375um 0.0375 1.3125
11 rs1110400_(T)snF MC1Rset3 11F T/C 0.1um 0.01 0.35
12 rs28777_(july)snF rs28777 - 5F+R 0.08 each F&R =0.4um 2.8 12F A/C 1.2um 0.12 4.2
13 Rs16891982_(T)snF Rs16891982 - 6F+R 0.08 each F&R =0.4um 2.8 13F G/C 0.9um 0.09 3.15
14 rs12821256_(T)snR rs12821256 - 7F+R 0.08 each F&R =0.4um 2.8 14R A/G 0.12um 0.03 1.05
15 rs4959270_(T)snF rs4959270 - 8F+R 0.08 each F&R =0.4um 2.8 15F C/A 0.3um 0.03 1.05
16 rs12203592_(T)snF rs12203592 - 9F+R 0.08 each F&R =0.4um 2.8 16F C/T 0.2um 0.02 0.7
17 rs1042602_(T)snR rs1042602 - 10F+R 0.08 each F&R =0.4um 2.8 17R G/T 1.25um 0.125 4.375
18 rs1800407_(T)snF rs1800407 - 11F+R 0.08 each F&R =0.4um 2.8 18F G/A 0.1um 0.01 0.35
19 rs2402130_(T)snF rs2402130 - 12F+R 0.08 each F&R =0.4um 2.8 19F A/G 0.75um 0.075 2.625
20 rs12913832_(T)snR rs12913832 - 13F+R 0.08 each F&R =0.4um 2.8 20R C/T 1um 0.25 8.75
21 rs2378249_(T)snR rs2378249 - 14F+R 0.08 each F&R =0.4um 2.8 21R T/C 0.1um 0.01 0.35
22 Rs12896399_(T)snF Rs12896399 - 15F+R 0.08 each F&R =0.4um 2.8 22F G/T 1um 0.1 3.5
23 Rs1393350_(DU)snR Rs1393350 - 16F+R 0.08 each F&R =0.4um 2.8 23R C/T 1.1um 0.11 3.85
24 rs683_(H)snR rs683 - 17F+R 0.08 each F&R =0.4um 2.8 24R T/G 0.3um 0.03 1.05
total 2,84ul 49.7 total 1.76 61.6
8/18/2015
no.samples no. of samples
Stocks PCR 1st set up (ul) Final conc 35 SBE reaction (ul) 35
primers 2.84 99.4 primers 1.76 61.6
10x PCR gold buffer (no mg) 1 1X 35 snapshot rxn mix 1 35
Mgcl2 (25mM) 1 2.5mM 35 H20 0.24 8.4
dNtps (10mM each,combo 40mM) 0.22 220 uM 7.7 1st PCR product 2
taq gold (5U/ul) 0.3 1.75U 10.5 5ul/rxn 105 total
H2O 3.64 127.4 Thermo conditions: SBE rxn
Total reagents 9 315 96 °C for 2 min and 25 cycles of 96 °C for 10 s, 50 °C for 5 s and 60 °C for 30 s
DNA 1
10ul total Clean up after SBE
Thermo conditions: 1st PCR Sap(1U/ul) 1ul used /sample (1)37°C - 45min, (2) 75°C - 15min
(1) 95 °C for 10 min, (2) 33 cycles of 95 °C for 30 s and 61 °C for 30 s, (3) 5 min at 61 °C.
CE run
Clean up after 1st PCR POP-7 on a 50 cm capillary length array. 
ExoProStar 2ul used per 5ul product of each sample (1)37°C - 45min, (2) 80°C - 15min Run parameters: injection voltage of 2.5 kV for 10 s, and run time of 500 s at 60 °C.
new made up XOSAP x no. of samples 35
1 EXOI 35
1 SAP 35
2 total total for all samples 70
65 
      
APPENDIX C 
Table 4 HIrisPlex-S Protocol 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No. SNP Primer set (all 50um stock)PCR Ps d STOCK(50um) 35 Dir SNPs tbc Conc p 10um(ul) 20um(ul) of 50um(ul) 35
1 rs3114908 F&R 0.1 each F&R =0.4um 3.5 1R C/T ct 0.08 0.07 2.45
2 rs1800414 F&R 0.1 each F&R =0.4um 3.5 2R T/C/A t 0.30 0.02 0.70
3 rs10756819 F&R 0.1 each F&R =0.4um 3.5 3F- new tail A/G ga 1.80 0.17 5.95
4 rs2238289 F&R 0.1 each F&R =0.4um 3.5 4F C/T ct 1.50 0.05 1.75
5 rs17128291 F&R 0.1 each F&R =0.4um 3.5 5R C/T ct 1.50 0.1 3.50
6 rs6497292 F&R 0.1 each F&R =0.4um 3.5 6R C/T ct 0.30 0.05 1.75
7 rs1129038 F&R 0.1 each F&R =0.4um 3.5 7F G/A ga 1.00 0.04 1.40
8 rs1667394 F&R 0.1 each F&R =0.4um 3.5 8R C/T ct 0.10 0.02 0.70
9 rs1126809 F&R 0.1 each F&R =0.4um 3.5 9F C/T ct 0.02 0.025 0.88
10 rs1470608 F&R 0.1 each F&R =0.4um 3.5 10R C/A ca 2.00 0.18 6.30
11 rs1426654 F&R 0.1 each F&R =0.4um 3.5 11F G/A ga 0.08 0.09 3.15
12 rs6119471 F&R 0.1 each F&R =0.4um 3.5 12R G/C gc 0.15 0.1 3.50
13 rs1545397 F&R 0.1 each F&R =0.4um 3.5 13F A/T at 1.00 0.08 2.80
14 rs6059655 F&R 0.1 each F&R =0.4um 3.5 14R C/T ct 1.50 0.4 14.00
15 rs12441727 F&R 0.1 each F&R =0.4um 3.5 15F C/T ga 0.10 0.07 2.45
16 rs3212355 F&R 0.1 each F&R =0.4um 3.5 16R G/A ga 1.20 0.15 5.25
17 rs8051733 F&R 0.1 each F&R =0.4um 3.5 17R C/T ct 1.60 0.16 5.60
Total primers (for both F&R) 119 59.5 total 1.78 62.125
no.samples no. of samples
Stocks PCR 1st set up (ul) Final conc 35 SBE reaction (ul) 35
primers 3.4 119 primers 1.775 62.125
10x PCR gold buffer (no mg) 1 1X 35 snapshot rxn mix 1 35
Mgcl2 (25mM) 1 2.5mM 35 H20 0.225 7.875
dNtps (10mM each,combo 40mM) 0.22 220 uM 7.7 1st PCR product 2
taq gold (5U/ul) 0.3 1.75U 10.5 5ul/rxn 105 total
H2O 3.08 107.8 Thermo conditions: SBE rxn
Total reagents 9 315 96 °C for 2 min and 25 cycles of 96 °C for 10 s, 50 °C for 5 s and 60 °C for 30 s
DNA 1
10ul total Clean up after SBE
Thermo conditions: 1st PCR Sap(1U/ul) 1ul used /sample (1)37°C - 45min, (2) 75°C - 15min
(1) 95 °C for 10 min, (2) 33 cycles of 95 °C for 30 s and 61 °C for 30 s, (3) 5 min at 61 °C.
CE run
Clean up after 1st PCR POP-7 on a 50 cm capillary length array. 
ExoProStar 2ul used per 5ul product of each sample as per description(1)37°C - 15min, (2) 80°C - 15min Run parameters: injection voltage of 2.5 kV for 10 s, and run time of 500 s at 60 °C.
new made up XOSAP into eosap-ITx no. of samples 35
1 EXOI 35
1 SAP 35
Trying this conc July 27th
2 total total for all samples 70
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APPENDIX D 
Table 5 Hair Morphology SNP Information 
 
Gene SNP Chromosome Location HG-19 Forward Miseq Primer Reverse Miseq Primer Product Size (with indexes and adapters) Reference
P2RY5 198607 13 48979167 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGTGGAAATGCAAGGACTCAGA 
GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGTGATTTCCCTTTTGTGGATTCT 218
PTK6 310642 20 62161998 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCTGGGCCAGTGAACAAGG GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGTGTGGAGCTGGGGACTC 281
FRAS1 436034 4 79256036 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGccttgaactcctgggctct GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGttcaggacaagcctgataacaa 250
CRCT1; 
near 
LCE3E
499697 1 152493154 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGAATCTGGGCAGAAGGGAAC GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGTCAATGGTTTAAAGATGCCAAA
225 Eriksson et al.
LIPH 505569 3 185236115 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGTTGTTTGTTTGTTTGCTTTTTGA  GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGACCTGGGAGACGGAGGATAC 211
LIPH 551936 3 185263467 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGTCCCTTGACGTGAGGAGTG GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGAACCTAGGTCTGACTCCAAAACTC 302
KRT71 585583 12 52929370 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGTTAAAAACAAAGGGAAGAAATGTT GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGTCCCACAAAGGTGATTTCAAG
312
KRT74 632205 12 52959307 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGTGAAAGCCTGTGTCCAAACT GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGCCAACTCAGATGAGGCTGCT 328
KRT74 670741 12 52965173 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGGTATCTCCCTGGAAGAGTCG    GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGAGTCAAGGTGGAGCTTCAGG 265
KRT74 673449 12 52965761 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGAGCCTCCTGGGCTGAAGT GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGCTGGCCAGCAGGAAGAGA 314
PRKAG3 692243 2 219695487 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGTTATGGAGGGACCTGAGGTAGA GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGACCAGCTGTGACCAGCA 316
VDR 731236 12 48238757 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGACGTCTGCAGTGTGTTGGAC  GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGTGGTGGGATTGAGCAGTG 249
IGFBP5 741384 2 217551954 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCAGGAAGGTCTGCCAGAAAG GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGGGTTAGGCAGAGGAAGGAC 252
HDAC9 756853 7 18890000 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGTTCCAACGATCTGAATGTGG       GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGATCCTCCCCTACGCTTTCAT 257 Marcinska et al. 
EBF1 929626 5 158310631 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCACCAGGAACTATGCTGAGGA GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGCTGCCAAAGCCTTAACTTCC 217 Marcinska et al. 
TCHH 1131471 1 152079989 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGGACACTGGCAAACTGATGA GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGCCAGCAGAAGGAGGAACAGA 274 Buket et al. 
FRAS1 1268789 4 79280693 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGGCTTGATTTAATAAAAATCAGTCAAC GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGCAGCTCCATCATATGCAATCC 204
Pospiech et al. 
near 
OFCC1
1556547 6 10270377 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCAGCATGTACTGCCTATTAACC GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGGATTGAAGACTGCTTGCTCTAT 224
Eriksson et al. 
IGFBP5 1978346 2 217561467 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGGAAGGTGGTGGTTTTAGCTT GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGAAGGTGTAACAGCCCACACC 229
1998076 20 21880045 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCACCAGGCAAATCTCAGG GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGTGCCTGTGGAAATGGTAGC 297 Marcinska et al.
1999874 10 8353101 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCTTAAACCTTGCCAGTGGA GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGCCACCAAATTCCAAAATTAGAGA 222
FLG-AS1 2050631 1 152312597 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGttgaatggatacagagtttcagc GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGTTTCTTTCAACATTGATTCCACA 308
2146114 1 152390621 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGAATGTTTGGCAAAAGCCTCTAT GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGAGGGAACCCAAAGAAAAGC 238
LGR4 2219783 11 27411298 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCTGATGAATTCAGGTCCAAG GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGAAAATGAATCAATGGGAATGAGTT 239
P2RY5 2227311 13 48987032 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGACTCCAAAGTTAATGTTTCTTTATGC GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGTGGGACAAATTGGGAATGTT 223
VDR 2228570 12 48272895 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGTGCAGCCTTCACAGGTCATA GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGCCCTGGCACTGACTCTG 292
VDR 2238136 12 48277713 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGTGGAGACCTCTGTCTTCCAG GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGGGCCAGCCCAGCTTAG 300
2489250 10 8274867 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGAGGCTGAGGCAGAAAACTG GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGTTTTTGTTGTTGTTGCTTTTTGTT 257
TRAF2 2784081 9 139791891 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGGCTCTGAAGGCCATGTGTA GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGTTTCCCTCCAGCCCCTA 294
RPTN 3001978 1 152126467 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGTTATCCACAGGAGCCAAAGC GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGTCTCCCTAAAGTTCAGAAACAGAAA 233
NBPF18P; 3007671 1 151999347 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCAGACTTCCAGTAGGGTGGA GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGACAGCCACTGTCAAACCACA 230
LOC10192
7949
3007681 1 152019357
TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGcgcccagcttattttctttg GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGagagtgagaccccacctcaa
272
3827760 2 109513601 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCGAGAAGACTAGCCGAATGC GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGTTAAGAAGGTAGAGGCTGAGCAC 255
IGFBP5 4442975 2 217920769 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCATGTGTTTATATTAAGTGCAGGTCA GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGCCTGCTCCTTGTTCATTTGC 256
IGFBP5 4480966 2 217560985 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGAGGTGACCAGTTGCCTTCAG GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGTCTGCAACTCACTGCTCTCAA 256
VDR 4516035 12 48299826 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGCTCACAAAATCATCCAGCA GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGCTCAATTTCCCACCCTTTCA 216
LOC39148 4672907 2 219821169 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGTGGAGTTGAAAGAGGCTTTAGG GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGAGCTCTCTGGGACTCGGTTT 258
IGFBP5 4674107 2 217536354 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGTTACAAGGCAGTGGGAGGAG GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGATTCAGCACCTGTTCCCCTA 292
SUCNR1/
MBNL1
4679955 3 151653368 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGAGTGGCTTAGCAGAGGGTTTT GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGCAAGTATTTATTATGCAAGAGTTTCA 
214 Marcinska et al.
near TCHH 4845418 1 152136230 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGACTGCACAAATAAGTTCCCATTTA GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGCCACTGACTCCCACAGATGTT
294 Medland et al. , Pospiech et al. 
CRNN; 
LCE5A
4845779 1 152479176 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGtccttggcttctgtcacctt GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGctggattatgcaggtggactc
258
up of AR 5919324 X 66430640 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCATAATTTCCAAATAACATGAGTTCAA GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGATGTGTTTCATGAAGGATGAGA
270 Marcinska et al.
PEX14 6658216 1 10561604 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCGCCCGGCTTTTTGTATTTT GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGAATAAACTAATAGGGGCAGGG 261
WNT10A 7349332 2 219756383 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGACATCCCAGCCCATACCAAC GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGACGTGGGAACCAGACCAAT 208 Medland et al. , Eriksson et al. , Pospiech et al. 
P2RY5 9535032 13 49012265 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGgcttggcactgGAATTTTATTT GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGagtgcttagaagggcacctg 297
P2RY5 9568036 13 48971936 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGTTTAGAGTCCTGATTCATTGACAAA GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGTCCCTTTTGTGTTTGCTTCC 213
9989836 2 70342727 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGTGGCCAGTTGAAAACTAAGATTC GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGAAAGCAAAACCAAGCCTAACAA 244
KRT71 10783518 12 52938497 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGAGATGCAGTTGCTGCTGTTG GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGCTCTCTGCCTGAGTGGGTGT 241
LOC10537
3470
10788819 1 151895093 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCAAGACAGGAATTCCAATAGAGAAA GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGCAAATTTTGGGGGAGACTGA
214
10788826 1 152161735 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCGGCCTAGGTCTTTCGTATC GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGCGGAAGCAGCTTTTCCTACTT 257
11150606 16 31099011 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCTCCTTGCCTCCTCACACTG GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGGGTGAGGTCAGGACAGGTA 256
11170678 12 54154174 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGGGTGAGAATTGGGAGATGA GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGGTCCAGATAAAGAACCTCCA 228
PADI3 11203346 1 17600822 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGAACTTGCAGGAAGGCTGTG GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGCTGCCTTATCACGGCAAGAC 261 Buket et al.
LOC10013
2111
11204897 1 151809066 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGtgggaggaataaatgGCTTG GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGACAGCCCTAGGCCAGAGAACT
252
11204925 1 152073120 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGTCTCGGTCCCCTGACCT GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGAGTTGGAGGTGCCTTTGAG 296
VDR 11568820 12 48302545 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGAAAGCAAACCAAGGGGTCTT GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGCATTGTAGAACATCTTTTGTATCAGGA 253
IGFBP5 11575161 2 217549963 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGTGACTGAGGAGCTGAATTT GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGCAAGGAGGTTGGATCACAAG 430
IGFBP5 11575194 2 217543728 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCGGTCCTTCTTCACTGCTTC GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGAGAGAGACTCCCGTGAGCA 238
RPTN 11582331 1 152134136 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCCTTTCTCTTGGCGTGT GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGATTAACTGATTGGCTGATCAACAT 303
PADI3 11585118 1 17605774 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCAGACACAGAGGCCAGAG GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGttGGGAATAAAGGTGGGTGA 239 Bucket et al.
TCHH 11803731 1 152083325 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGTCCTCCTCCGGGAGAAAC GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGGACTTCACATGGCAGTGG 254 Medland et al. , Buket et al. , Pospiech et al. 
12116760 1 152437883 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGGTCAGTGTTAGCGAGCTGTT    GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGCAGGAAGAAAAAGAGGGAATCA 230
12123907 1 152467751 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGAGGGAGAGGTGGAGCATC GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGTCTCCAGGATTTACTGCCATTT 208
near TCHH 12130862 1 152027015 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGTTTTCTGAGGGAAGTTTGTTCT GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGAGGAAGAGGCAAAATGGTCA
242 Medland et al ., Buket et al. , Pospiech et al. 
TARDBP 12565727 1 11033082 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGTCTGTTTACCTGGGGCATTG GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGTTTAGTCTTGAGCCCCTCCA 224 Li et al. , Marcinska et al.
HERC2 12913832 15 28365618 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCTCTGTGTCTGATCCAAGAGG GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGAACAATTAATTAAAAACAAAGAGAAGC 227
12997742 2 70786598 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGCAGGCAAAAATAAACCACA GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGCTAGGATTACAGTTGCCCACAA 301
IGFBP5 13015993 2 217625523 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGAGACACCAAGGAGGGAGGAT GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGTGACATCCGTCTTTGTCAGG 225
TCHHL1 17646946 1 152062767 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGTTCTCAGCATCCTCCCAAAG GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGCTCCAGAGCAGGAAGATATAA 282 Medland et al. , Eriksson et al. , Pospiech et al. 
KRT71 17662023 12 52934349 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGAGGGATGATGAAGGAGCTG GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGCCTGCACTTCAAACCCAGAG 218
KRT71 17730088 12 52946336 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCAGTAGAAATTGACCTGCCTCTG GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGTCTTCTTGGAACATACGATTTTGT 279
LIPH 55854644 3 185226492 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGGCTATTTCTGACTTGCCCTA GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGTTTGAAAGCTTCACCTCACCT 273
55883933 1 151889447 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGCTGATGTGGGAGGATGACT GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGGTCTAGCTCTGTCACCCAGA 209
FLG-AS1 61816764 1 152308971 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGCACTTCCCTGGTGATGAA GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGTCTGTGTTTATGACCCCCAAA 243
IGFBP5 67587000 2 217561648:50 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGACATTGTGCTTCCTCCCTTG GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGTTTCTTGAAAGCAGTCCTCCA 237
TCHH 72696935 1 152085951 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGAAAGAATAACACAAGTTCGCTTT GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGCTGGCTGCTTCAGACAGAAA 223 Bucket et al.
RPTN 72696940 1 152128121 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGTCTGGCTGACCATAGTGGAA GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGCTACAGTCAGCCAGACAAACAA 270
KRT74 73107581 12 52967117 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCAGCAGGAAAACTGCTCAGG  GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGTGGACCCTGAGATCCAGAAG 253
WNT10A 74333950 2 219746292 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGAGGTGGGGTCAGTGAGAGAC GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGATGGGCACACATACAAACTACTGTT 240
HRNR 74868796 1 152191051 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGAAGACCACCCTGAGCCAGA GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGAGGAGCGAACAACATGGATC 307
75203436 1 151842358 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCCAGCCAATGAAGTTTTGT GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGCAGCTTGCAAATTAGAAAGGAA 264
RPTN 75957773 1 152127455 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGTGTGTCCCACATGGACCTT GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGAGTAGTGAGCAGGGCCACAG 246
LINC0149 77157375 2 219779911 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGGGAGAAGCAGGACAAAACA GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGTCAGGGCAGGTTCCAAGT 222
RPTN 78544048 1 152129087 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCAAAGCTGAAATCCTTGTCTTG GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGGCAGAACTCCCACCACA 305
80293268 1 8207579 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGAGAAAGCAAGCAGCTCACCT GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGAGAAGTGAGTGGGCAGCATC 229
114410520 1 151972609 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGCTGTGCTTGCTGTGCTAAC GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGTTTGCAGCTCACCTGTAGGA 247
LINC0152
7
115813648 1 152921586 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGCCACACTTCACACTTGCAG GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGAGATGCATGTCAGGAAAGATGA
258
140371183 1 152098428 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGTTGTTGCCTGCATGGAGAT GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGAGCATAGGTTTGTTCTAACCACA 242
KRTAP2-3 143290289 17 39216977 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCAAAGCTGCTAGACTGATTTTATT   GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGTGAAAGCTATTTTTCTTTCCTTTCC
253
LIPH 144288709 3 185236964 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGTGAATCAGAGAGGAAACTGCTG  GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGCCAGGATTATAGGAATGGCAAG 233
151069963 1 152004241 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGAAGGAATCAGAGGTTTTCTGGA GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGTCCAGGGTTAAAGATGACAGATT 237
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APPENDIX E 
Table 6 Group 1 Hair Structure Miseq Assay Protocol 
 
No. SNP Primer set PCR Ps d STOCK(50um) 205
1 1268789 forward and reverse 0.08 Forward & 0.08 Reverse 16.40
2 7349332 forward and reverse 0.1 Forward & 0.1 Reverse 20.50
3 55883933 forward and reverse 0.1 Forward & 0.1 Reverse 20.50
4 505569 forward and reverse 0.1 Forward & 0.1 Reverse 20.50
5 10788819 forward and reverse 0.08 Forward & 0.08 Reverse 16.40
6 198607 forward and reverse 0.07 Forward & 0.07 Reverse 14.35
7 1999874 forward and reverse 0.08 Forward & 0.08 Reverse 16.40
8 12565727 forward and reverse 0.08 Forward & 0.08 Reverse 16.40
9 499697 forward and reverse 0.08 Forward & 0.08 Reverse 16.40
10 13015993 forward and reverse 0.08 Forward & 0.08 Reverse 16.40
11 11170678 forward and reverse 0.08 Forward & 0.08 Reverse 16.40
12 1978346 forward and reverse 0.08 Forward & 0.08 Reverse 16.40
13 12116760 forward and reverse 0.07 Forward & 0.07 Reverse 14.35
14 144288709 forward and reverse 0.08 Forward & 0.08 Reverse 16.40
15 67587000 forward and reverse 0.08 Forward & 0.08 Reverse 16.40
16 11575194 forward and reverse 0.08 Forward & 0.08 Reverse 16.40
17 114410520 forward and reverse 0.07 Forward & 0.07 Reverse 14.35
18 3827760 forward and reverse 0.08 Forward & 0.08 Reverse 16.40
19 4442975 forward and reverse 0.08 Forward & 0.08 Reverse 16.40
20 11150606 forward and reverse 0.08 Forward & 0.08 Reverse 16.40
21 756853 forward and reverse 0.08 Forward & 0.08 Reverse 16.40
22 2489250 forward and reverse 0.08 Forward & 0.08 Reverse 16.40
23 10788826 forward and reverse 0.08 Forward & 0.08 Reverse 16.40
24 5919324 forward and reverse 0.08 Forward & 0.08 Reverse 16.40
25 3007681 forward and reverse 0.1 Forward & 0.1 Reverse 20.50
26 55854644 forward and reverse 0.08 Forward & 0.08 Reverse 16.40
27 17730088 forward and reverse 0.08 Forward & 0.08 Reverse 16.40
28 9535032 forward and reverse 0.1 Forward & 0.1 Reverse 20.50
29 551936 forward and reverse 0.08 Forward & 0.08 Reverse 16.40
30 11582331 forward and reverse 0.1 Forward & 0.1 Reverse 20.50
31 74868796 forward and reverse 0.08 Forward & 0.08 Reverse 16.40
32 673449 forward and reverse 0.08 Forward & 0.08 Reverse 16.40
1086.5 543.25
no.samples
Stocks PCR 1st set up (ul) Final conc 205
primers 5.3 1086.50
10x PCR gold buffer (no mg) 1 1X 205
Mgcl2 (25mM) 1 2.5mM 205
dNtps (10mM each,combo 40mM) 0.22 220 uM 45.1
taq gold (5U/ul) 0.4 1.75U 82
H2O 1.08 221.4
Total reagents 9 1845
DNA 1
10ul total
Thermo conditions: 1st PCR
(1) 95 °C for 10 min, (2) 28 cycles of 95 °C for 30 s and touchdown at 64 °C decreasing by 0.3 for 40 s, (3) 5 min at 60 °C.
68 
      
APPENDIX F 
Table 7 Group 2 Hair Structure Miseq Assay Protocol 
 
 
 
 
No. SNP Primer set PCR Ps d STOCK(50um) 205
1 12123907 forward and reverse 0.1 Forward & 0.1 Reverse 20.50
2 9568036 forward and reverse 0.07 Forward & 0.07 Reverse 14.35
3 4679955 forward and reverse 0.07 Forward & 0.07 Reverse 14.35
4 929626 forward and reverse 0.08 Forward & 0.08 Reverse 16.4
5 77157375 forward and reverse 0.08 Forward & 0.08 Reverse 16.4
6 72696935 forward and reverse 0.08 Forward & 0.08 Reverse 16.4
7 1556547 forward and reverse 0.07 Forward & 0.07 Reverse 14.35
8 80293268 forward and reverse 0.08 Forward & 0.08 Reverse 16.4
9 151069963 forward and reverse 0.08 Forward & 0.08 Reverse 16.4
10 2219783 forward and reverse 0.08 Forward & 0.08 Reverse 16.4
11 10783518 forward and reverse 0.08 Forward & 0.08 Reverse 16.4
12 140371183 forward and reverse 0.08 Forward & 0.08 Reverse 16.4
13 61816764 forward and reverse 0.08 Forward & 0.08 Reverse 16.4
14 9989836 forward and reverse 0.08 Forward & 0.08 Reverse 16.4
15 731236 forward and reverse 0.1 Forward & 0.1 Reverse 20.5
16 436034 forward and reverse 0.08 Forward & 0.08 Reverse 16.4
17 143290289 forward and reverse 0.08 Forward & 0.08 Reverse 16.4
18 4480966 forward and reverse 0.08 Forward & 0.08 Reverse 16.4
19 4672907 forward and reverse 0.07 Forward & 0.07 Reverse 14.35
20 115813648 forward and reverse 0.08 Forward & 0.08 Reverse 16.4
21 6658216 forward and reverse 0.2 Forward & 0.2 Reverse 41
22 11203346 forward and reverse 0.1 Forward & 0.1 Reverse 20.5
23 1131471 forward and reverse 0.08 Forward & 0.08 Reverse 16.4
24 17646946 forward and reverse 0.08 Forward & 0.08 Reverse 16.4
25 4674107 forward and reverse 0.08 Forward & 0.08 Reverse 16.4
26 12997742 forward and reverse 0.08 Forward & 0.08 Reverse 16.4
27 2050631 forward and reverse 0.1 Forward & 0.1 Reverse 20.5
28 632205 forward and reverse 0.08 Forward & 0.08 Reverse 16.4
984 492.00
no.samples
Stocks PCR 1st set up (ul) Final conc 205
primers 4.8 984.00
10x PCR gold buffer (no mg) 1 1X 205
Mgcl2 (25mM) 1 2.5mM 205
dNtps (10mM each,combo 40mM) 0.22 220 uM 45.1
taq gold (5U/ul) 0.4 1.75U 82
H2O 1.58 323.9
Total reagents 9 1845
DNA 1
10ul total
Thermo conditions: 1st PCR
(1) 95 °C for 10 min, (2) 33 cycles of 95 °C for 30 s and 61 °C for 30 s, (3) 5 min at 61 °C.
69 
      
APPENDIX G 
Table 8 Group 3 Hair Structure Miseq Assay Protocol 
 
 
 
No. SNP Primer set PCR Ps d STOCK(50um) 205
1 1268789 forward and reverse 0.08 Forward & 0.08 Reverse 16.40
2 7349332 forward and reverse 0.1 Forward & 0.1 Reverse 20.50
3 55883933 forward and reverse 0.1 Forward & 0.1 Reverse 20.50
4 505569 forward and reverse 0.1 Forward & 0.1 Reverse 20.50
5 10788819 forward and reverse 0.08 Forward & 0.08 Reverse 16.40
6 198607 forward and reverse 0.07 Forward & 0.07 Reverse 14.35
7 1999874 forward and reverse 0.08 Forward & 0.08 Reverse 16.40
8 12565727 forward and reverse 0.08 Forward & 0.08 Reverse 16.40
9 499697 forward and reverse 0.08 Forward & 0.08 Reverse 16.40
10 13015993 forward and reverse 0.08 Forward & 0.08 Reverse 16.40
11 11170678 forward and reverse 0.08 Forward & 0.08 Reverse 16.40
12 1978346 forward and reverse 0.08 Forward & 0.08 Reverse 16.40
13 12116760 forward and reverse 0.07 Forward & 0.07 Reverse 14.35
14 144288709 forward and reverse 0.08 Forward & 0.08 Reverse 16.40
15 67587000 forward and reverse 0.08 Forward & 0.08 Reverse 16.40
16 11575194 forward and reverse 0.08 Forward & 0.08 Reverse 16.40
17 114410520 forward and reverse 0.07 Forward & 0.07 Reverse 14.35
18 3827760 forward and reverse 0.08 Forward & 0.08 Reverse 16.40
19 4442975 forward and reverse 0.08 Forward & 0.08 Reverse 16.40
20 11150606 forward and reverse 0.08 Forward & 0.08 Reverse 16.40
21 756853 forward and reverse 0.08 Forward & 0.08 Reverse 16.40
22 2489250 forward and reverse 0.08 Forward & 0.08 Reverse 16.40
23 10788826 forward and reverse 0.08 Forward & 0.08 Reverse 16.40
24 5919324 forward and reverse 0.08 Forward & 0.08 Reverse 16.40
25 3007681 forward and reverse 0.1 Forward & 0.1 Reverse 20.50
26 55854644 forward and reverse 0.08 Forward & 0.08 Reverse 16.40
27 17730088 forward and reverse 0.08 Forward & 0.08 Reverse 16.40
28 9535032 forward and reverse 0.1 Forward & 0.1 Reverse 20.50
29 551936 forward and reverse 0.08 Forward & 0.08 Reverse 16.40
30 11582331 forward and reverse 0.1 Forward & 0.1 Reverse 20.50
31 74868796 forward and reverse 0.08 Forward & 0.08 Reverse 16.40
32 673449 forward and reverse 0.08 Forward & 0.08 Reverse 16.40
1086.5 543.25
no.samples
Stocks PCR 1st set up (ul) Final conc 205
primers 5.3 1086.50
10x PCR gold buffer (no mg) 1 1X 205
Mgcl2 (25mM) 1 2.5mM 205
dNtps (10mM each,combo 40mM) 0.22 220 uM 45.1
taq gold (5U/ul) 0.4 1.75U 82
H2O 1.08 221.4
Total reagents 9 1845
DNA 1
10ul total
Thermo conditions: 1st PCR
(1) 95 °C for 10 min, (2) 28 cycles of 95 °C for 30 s and touchdown at 64 °C decreasing by 0.3 for 40 s, (3) 5 min at 60 °C.
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Table 9 Miseq Dilution Calculator [50] 
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Coding Used for Conversion and Alignment of Miseq Fastq File 
SAMtools command to convert fai file to fasta file 
faidx /Users/username/file_location/folder_name/test.fasta 
Alignment of sample files to create .sam file 
bwa mem -t 8 test.fasta / 
Users/username/file_location/folder_name/subfolder_1/subfolder_2/subfolder_3/sample1 
_L001_R1_001.fastq/Users/username/file_location/folder_name/subfolder_1/subfolder_2
/subfolder_3/sample1 _L001_R2_001.fastq >/Users/username/file_location/ 
folder_name/subfolder_1/subfolder_2/test.sam 
Use of Picard tools to convert .sam to .bam file 
picard AddOrReplaceReadGroups 
I=/Users/username/file_location/folder_name/subfolder_1/subfolder_2/subfolder_3/test.s
am  O= 
Users/username/file_location/folder_name/subfolder_1/subfolder_2/subfolder_3/test.bam        
RGID=4       RGLB=lib1       RGPL=illumina       RGPU=unit1 RGSM=20 
Sort the .bam File 
SAMtools sort / 
Users/username/file_location/folder_name/subfolder_1/subfolder_2/test.bam > / 
Users/username/file_location/folder_name/subfolder_1/subfolder_2 /test-sorted.bam 
Create Searchable Reference File 
picard CreateSequenceDictionary Reference=/ 
Users/username/file_location/folder_name/test.fasta OUTPUT=/ 
Users/username/file_location/folder_name/ test.dict 
SAMtools used to create bcf and vcf files 
SAMtools mpileup -f / Users/username/file_location/folder_name/test.fasta -g / 
Users/username/file_location/folder_name/subfolder_1/subfolder_2/subfolder_3/test-
sorted.bam | bcftools call -m - > / 
Users/username/file_location/folder_name/subfolder_1/subfolder_2/subfolder_3/calls.vcf 
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Use of GATK for Compilation and Visualization 
java -jar GenomeAnalysisTK.jar -T VariantsToTable -R / 
Users/username/file_location/folder_name /ref.fasta -V / 
Users/username/file_location/folder_name/ testcalls.vcf -F CHROM -F POS -F ID -F 
REF -F ALT -F QUAL -F FILTER -F INFO --allowMissingData -o results.table 
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Table 10 Plates for Miseq Validation Assay 
 
 
 
 
Plate 1
1
2
3
4
5
6
7
8
9
10
11
12
A
1905     
500pg
648       
500pg
1854   
500pg
1539   
500pg
1497   
500pg
1947   
500pg
1938:1092 
1ng:1ng
1497:1905 
1ng:500pg
1155:1004 
100pg:500pg
1938:290    
1ng:100pg
1188:1155:1938 
1ng:1ng:500pg
1938:290    
1ng:1ng
B
1757     
500pg
1080     
500pg
1547   
500pg
1201    
500pg
1550   
500pg
2156   
500pg
1497:1905 
1ng:1ng
1155:1004 
1ng:500pg
1938:290    
100pg:500pg
1550:429 
5ng:500pg
1092:1550:1004 
500pg:1ng:500pg
1550:429 
1ng:500pg
C
1775    
500pg
401      
500pg
1938   
500pg
1092   
500pg
346      
500pg
1004     
500pg
1155:1004 
1ng:1ng
1938:290    
1ng:500pg
1550:429 
1ng:100pg
1188:429 
5ng:500pg
1550:429   
1ng:1ng
1188:429 
1ng:500pg
D
1539     
500pg
1497     
500pg
1947   
500pg
1188   
500pg
625      
500pg
1992      
500pg
1938:290    
1ng:1ng
1550:429 
100pg:500pg
1188:429 
1ng:100pg
1992:1201 
5ng:500pg
1188:429   
1ng:1ng
1992:1201 
1ng:500pg
E
1201    
500pg
1550     
500pg
2156   
500pg
429     
500pg
1573   
500pg
290       
500pg
1550:429 
1ng:500pg
1188:429 
100pg:500pg
1992:1201 
1ng:100pg
1938:1092 
5ng:500pg
1992:1201 
1ng:1ng
1938:1092 
1ng:500pg
F
1092     
500pg
346      
500pg
1905   
500pg
648     
500pg
1854   
500pg
1550:429 
1ng:1ng
1188:429 
1ng:500pg
1992:1201 
100pg:500pg
1938:1092 
1ng:100pg
1497:1905 
5ng:500pg
1938:1092 
1ng:1ng
1497:1905 
1ng:500pg
G
1188     
500pg
625      
500pg
1757     
500pg
1080   
500pg
1547   
500pg
1188:429 
1ng:1ng
1992:1201 
1ng:500pg
1938:1092 
100pg:500pg
1497:1905 
1ng:100pg
1155:1004 
5ng:500pg
1497:1905 
1ng:1ng
1155:1004 
1ng:500pg
H
429       
500pg
1573     
500pg
1775    
500pg
401      
500pg
1938   
500pg
1992:1201 
1ng:1ng
1938:1092 
1ng:500pg
1497:1905 
100pg:500pg
1155:1004 
1ng:100pg
1938:290    
5ng:500pg
1155:1004 
1ng:1ng
1938:290    
1ng:500pg
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Table 10 Continued 
 
 
 
 
 
 
 
 
Plate 2
1
2
3
4
5
6
7
8
9
10
11
12
A
1550:429 
100pg:500pg
1188:429 
1ng:100pg
1992:1201 
5ng:500pg
1155-5 m
in          
500pg
1550-20 
m
in          
500pg
 9947A       
50pg
 9947A       
50pg
007        
50pg
007        
50pg
W
et saliva 
Charanya 
1
Cat             
1ng
Sem
en/fem
a
le 
freezer/W
al
sh 2
B
1188:429 
100pg:500pg
1992:1201 
1ng:100pg
1938:1092 
5ng:500pg
1155-10 
m
in          
500pg
1550-30 
m
in          
500pg
 9947A       
25pg
 9947A       
25pg
 007        
25pg
 007        
25pg
D
ried&
D
eg
raded 
saliva 
Charanya 
Prim
ate        
1ng
W
et saliva 
Charanya 2
C
1992:1201 
100pg:500pg
1938:1092 
1ng:100pg
1497:1905 
5ng:500pg
1155-20 
m
in          
500pg
1550-40 
m
in          
500pg
 9947A       
10pg
 9947A       
10pg
 007       
10pg
 007       
10pg
Touch D
N
A 
fresh 
W
esli 1
Pig             
1ng
D
ried&
degr
aded saliva 
Charanya 2
D
1938:1092 
100pg:500pg
1497:1905 
1ng:100pg
1155:1004 
5ng:500pg
1155-30 
m
in          
500pg
9947A        
5ng
9947A        
5ng
007            
5ng
007         
5ng
Stephanie     
dried 
blood
H
air - D
N
A 
Ryan 1
M
ouse          
1ng
Touch D
N
A 
fresh W
esli 
2
E
1497:1905 
100pg:500pg
1155:1004 
1ng:100pg
1938:290    
5ng:500pg
1155-40 
m
in          
500pg
 9947A      
1ng
 9947A      
1ng
 007           
1ng
 007        
1ng
Stephanie     
w
et blood
Touch D
N
A 
degraded 
W
esli 1
Stephani
e     dried 
blood 2
H
air - D
N
A 
Ryan 2
F
1155:1004 
100pg:500pg
1938:290    
1ng:100pg
1188:1155:1938 
1ng:1ng:500pg
1550-0 m
in          
500pg
9947A       
500pg
9947A       
500pg
007       
500pg
007       
500pg
…
N
oah's 
D
N
A w
ith 
Charanya'
s hem
e 
cont (conc-
1ul) 
Vaginal 
Sw
ab 
Krystal 1
Stephani
e     w
et 
blood 2
Touch D
N
A 
degraded 
W
esli 2
G
1938:290    
100pg:500pg
1550:429 
5ng:500pg
1092:1550:1004 
500pg:1ng:500p
g
1550-5 m
in          
500pg
 9947A       
250pg
 9947A       
250pg
 007       
250pg
 007       
250pg
W
et 
sem
en 
frozen 
sam
ple 1
Vaginal 
Sw
ab/Sem
en - 
Krystal/fre
ezer 1
N
oah's 
D
N
A w
ith 
Charanya
's hem
e 
cont 
(diluted-
0.1uL) 
Vaginal 
Sw
ab 
Krystal 2
H
1550:429 
1ng:100pg
1188:429 
5ng:500pg
1155-0 m
in          
500pg
1550-10 
m
in          
500pg
 9947A       
100pg
 9947A       
100pg
 007       
100pg
 007       
100pg
Sem
en/fe
m
ale 
freezer/W
alsh 1
D
og                  
1ng
W
et 
sem
en 
frozen 
sam
ple 2
Vaginal 
Sw
ab/Sem
e
n - 
Krystal/free
zer 2
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Table 11 Distribution of Samples during Optimization Run 
 
 
 
500pg Samples (Ran in Duplicate) Population Eye Color Hair Color Skin Color
Sample1905 Mexico Dark Brown Dark Brown Type 4
Sample1757 Vietnam Dark Brown Black Type 4
Sample1775 European Blue/Blue Gray Blond Type 4
Sample1539 African- EuropeanDark Brown Dark Brown Type 5
Sample1201 African Dark Brown Dark Brown Type 5
Sample1092 China Dark Brown Black Type 3
Sample1188 European Blue/Green Yellow Light Red/Strawberry Blond Type 1
Sample429 European Blue/Green Yellow Dark Brown Type 3
Sample648 European Blue/Green Yellow Red Brown/Auburn Type 2
Sample1080 Panama Dark Brown Dark Brown Type 4
Sample401 European Blue/Green Yellow Light Red/Strawberry Blond Type 2
Sample1497 European Blue/Blue Gray Blond Type 2
Sample1550 European Blue/Blue Gray Light Brown Type 2
Sample346 European Hazel/Light Brown Light Brown Type 2
Sample625 Vietnam Dark Brown Black Type 4
Sample1573 European Blue/Blue Gray Dark Brown Type 2
Sample1854 European Blue/Blue Gray Blond Type 2
Sample1547 European Hazel/Light Brown Red Brown/Auburn Type 2
Sample1938 European Hazel/Light Brown Light Brown Type 3
Sample1947 European Hazel/Light Brown Red Brown/Auburn Type 2
Sample 2156 European Blue/Green Yellow Blond Type 2
Sample1004 African Dark Brown Black Type 5
Sample290 Iran Dark Brown Dark Brown Type 3
Sample 1992 European Hazel/Light Brown Light Brown Type 1
Hair
Degraded Touch DNA
Vaginal Swab
VaginalSwab with Semen
Wet Blood
Heme Contaminated Sample
Seman-Saliva (male-female) Mixture
Saliva
Degraded Saliva
Touch DNA
Three Person Mixture
1ng:500pg:500pg
Sample1188:1155:1938
Sample1092:1550:1004
Casework Samples
Dried Blood
Sample1938:290
Sample1550:429
Sample1188:429
Sample1992:690
Sample1938:1092
Sample1497:1905
Sample1155:1004
Sample1938:290
Sample1550:429
Sample1188:429
Sample1992:690
Sample1938:1092
Sample1497:1905
Sample1155:1004
Sample1938:290
Sample1550:429
Sample1188:429
Sample1992:690
Sample1938:1092
Sample1497:1905
Sample1155:1004
Sample1938:290
Optimazation Run 
Sample1938:290
Sample1155:1004
Sample1497:1905
Sample1938:1092
Sample1992:690
Sample1188:429
Sample1550:429
Sample1550:429
Sample1188:429
Mixture Samples
1ng:1ng
1ng:500pg
100pg:500pg
1ng :100pg
5ng:500pg
Sample1992:690
Sample1938:1092
Sample1497:1905
Sample1155:1004
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Table 12 HIrisPlex-S MPS Primer Sequences 
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Table 13 HIrisPlex-S MPS Protocol 
 
No. SNP Primer set PCR Ps d STOCK(50um) 1.000
1 MC1Rset1 forward and reverse 0.08 Forward & 0.08 Reverse 0.080
2 MC1Rset2 forward and reverse 0.11 Forward & 0.11 Reverse 0.110
3 MC1Rset3 forward and reverse 0.06 Forward & 0.06 Reverse 0.060
4 MC1Rset4 forward and reverse 0.03 Forward & 0.03 Reverse 0.030
5 rs28777 forward and reverse 0.08 Forward & 0.08 Reverse 0.080
6 rs16891982 forward and reverse 0.06 Forward & 0.06 Reverse 0.060
7 rs12821256 forward and reverse 0.10 Forward & 0.10 Reverse 0.100
8 rs4959270 forward and reverse 0.04 Forward & 0.04 Reverse 0.040
9 rs12203592 forward and reverse 0.04 Forward & 0.04 Reverse 0.040
10 rs1042602 forward and reverse 0.07 Forward & 0.07 Reverse 0.070
11 rs1800407 forward and reverse 0.035 Forward & 0.035 Reverse 0.035
12 rs2402130 forward and reverse 0.03 Forward & 0.03 Reverse 0.030
13 rs12913832 forward and reverse 0.02 Forward & 0.02 Reverse 0.020
14 rs2378249 forward and reverse 0.045 Forward & 0.045Reverse 0.045
15 rs12896399 forward and reverse 0.075 Forward & 0.075 Reverse 0.075
16 rs1393350 forward and reverse 0.06 Forward & 0.06 Reverse 0.060
17 rs683 forward and reverse 0.09 Forward & 0.09 Reverse 0.090
18 rs3114908 forward and reverse 0.02 Forward & 0.02 Reverse 0.020
19 rs1800414 forward and reverse 0.09 Forward & 0.09 Reverse 0.090
20 rs10756819 forward and reverse 0.02 Forward & 0.02 Reverse 0.020
21 rs2238289 forward and reverse 0.04 Forward & 0.04 Reverse 0.040
22 rs17128291 forward and reverse 0.045 Forward & 0.045 Reverse 0.045
23 rs6497292 forward and reverse 0.05 Forward & 0.05 Reverse 0.050
24 rs1129038 forward and reverse 0.04 Forward & 0.04 Reverse 0.040
25 rs1667394 forward and reverse 0.045 Forward & 0.045 Reverse 0.045
26 rs1126809 forward and reverse 0.04 Forward & 0.04 Reverse 0.040
27 rs1470608 forward and reverse 0.10 Forward & 0.10 Reverse 0.100
28 rs1426654 forward and reverse 0.055 Forward & 0.055 Reverse 0.055
29 rs6119471 forward and reverse 0.12 Forward & 0.12 Reverse 0.120
30 rs1545397 forward and reverse 0.10 Forward & 0.10 Reverse 0.100
31 rs6059655 forward and reverse 0.04 Forward & 0.04 Reverse 0.040
32 rs12441727 forward and reverse 0.05 Forward & 0.05 Reverse 0.050
33 rs3212355 forward and reverse 0.075 Forward & 0.075 Reverse 0.075
34 rs8051733 forward and reverse 0.05 Forward & 0.05 Reverse 0.050
Stocks PCR 1st set up (ul) Final conc 110.000
primers 3.93 432.300
10x PCR gold buffer (no mg) 1 1X 110.000
Mgcl2 (25mM) 1 2.5mM 110.000
dNtps (10mM each,combo 40mM) 0.22 220 uM 24.200
taq gold (5U/ul) 0.4 1.75U 44.000
H2O 2.45 269.500
Total reagents 9 990.000
DNA 1
10ul total
Thermo conditions: 1st PCR
(1) 95 °C for 10 min, (2) 34 cycles of 95 °C for 30 s and touchdown at 62 °C decreasing by 0.3 for 40 followed  by 60 °C for 10s  (3) 5 min at 60 °C.
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Table 14 Concordance Testing Results for HIrisPlex-S 
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Coding Used for Correlation and Partial Correlation for Hair Structure Assay 
 
Used for Correlation- No Control for Variables 
dat <- hstestcorr[,c(1,2:95)] 
for(i in 2:92){ 
  x <- dat[i] 
  subs <- cbind.data.frame(x,dat[,c(93:95)]) 
  subs_rm <- na.omit(subs) 
  test[[i]] <- cor.test(subs_rm[,1],subs_rm$Hair.Type, method = "pearson") 
  head(test[[i]]) 
  corr <- cbind(test[[i]]$estimate, test[[i]]$p.value) 
  write.table(corr, file="C:/Users/krcli/Desktop/test_corr_trial3.txt", sep=" ", 
row.names=TRUE, col.names = TRUE, append = TRUE) 
} 
Used for Partial Correlation- Controling for Age and Sex 
dat <- hstestcorr[,c(1,2:95)] 
for(i in 2:92){ 
  x <- dat[i] 
  subs <- cbind.data.frame(x,dat[,c(93:95)]) 
  subs_rm <- na.omit(subs) 
  test[[i]] <- pcor.test(subs_rm[,1], subs_rm$Hair.Type, subs_rm[,c(2:3)], method = 
"pearson") 
  write.table(test[[i]], file="C:/Users/krcli/Desktop/test_pc_trial3.txt", sep=" ", 
row.names=TRUE, col.names = TRUE, append = TRUE) 
  } 
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Table 15 Pearson’s Correlation with No Corrections 
 
 
Number Estimate p.value N, after removing NA Overall Mega analysis US pop-MEGA
rs10783518-C -0.07196 0.018298 1077
rs10788819-T -0.05064 0.098121 1070
rs10788826-T -0.02115 0.492296 1058
rs11150606-C -0.13352 1.19E-05 1071
rs11170678-G -0.04052 0.185773 1070
rs11203346-G -0.00098 0.974461 1080
rs11204897- G -0.06719 0.039868 938
rs11204925-G 0.012714 0.734852 714
rs1131471-T -0.07217 0.018065 1075
rs114410520-C -0.05841 0.057893 1057
rs11568820-T 0.176335 6.41E-08 930
rs11575161-T 0.010358 0.789914 666 SIGNIFICANT
rs11575194-A -0.04187 0.171484 1070
rs115813648-C -0.00154 0.959913 1064
rs11582331-T 0.023025 0.459111 1038
rs11585118-A -0.01744 0.58218 1000
rs11803731-T -0.1619 3.03E-07 992
rs12116760-T -0.05478 0.074485 1063
rs12123907-A -0.02596 0.394852 1078
rs12130862-T -0.10065 0.003518 841
rs12565727-G 0.094649 0.001828 1084
rs1268789-T 0.037382 0.219639 1082
rs12913832-G -0.16526 1.72E-06 831
rs12997742-C -0.10389 0.00085 1030
rs13015993-G 0.033714 0.268966 1079
rs140371183-G 0.034028 0.26542 1075 SIGNIFICANT
rs143290289-A -0.09478 0.002099 1053
rs144288709-A 0.027873 0.360358 1081
rs151069963-C -0.02824 0.357164 1067
rs1556547-A 0.031951 0.29527 1077
rs17646946-A -0.13181 2.12E-05 1036
rs17662023-A -0.0423 0.166593 1073
rs17730088-G -0.01493 0.628358 1055
rs1978346-A 0.002175 0.943356 1072
rs198607-C -0.02933 0.343145 1049
rs1998076-A -0.01781 0.58372 951
rs1999874-A 0.056195 0.069259 1048
rs2050631-G -0.09201 0.003426 1012
rs2146114-C 0.046945 0.12629 1064
rs2219783-G 0.157161 2.54E-07 1067 SIGNIFICANT SIGNIFICANT
rs2227311-G -0.02394 0.48561 853
rs2228570-A -0.05372 0.094816 970
rs2238136-T 0.002389 0.942632 912
rs2489250-T -0.05601 0.065789 1082 SIGNIFICANT
rs2784081-C -0.02849 0.352512 1069
rs3001978-T -0.0623 0.064266 885
rs3007671-T -0.01214 0.692493 1066
rs3007681-C -0.0357 0.249994 1042
rs310642-C 0.18404 5.94E-09 987
rs3827760-G -0.15983 1.47E-07 1072
rs436034-T -0.04142 0.177773 1062
rs4442975-G 0.10475 0.000632 1063
rs4480966-C -0.01233 0.687783 1066
rs4516035-C -0.09635 0.002382 994
rs4672907-A 0.190473 3.70E-10 1067
rs4674107-C -0.10147 0.000939 1062
rs4679955-T -0.0387 0.211476 1046
rs4845418-C -0.13944 2.17E-05 923
rs4845779-T 0.042728 0.170605 1032
rs499697-G -0.02964 0.333403 1069
rs505569-G 0.00497 0.870827 1075
rs551936-C -0.00755 0.804531 1078
rs55854644-T -0.0435 0.158362 1055
rs55883933-C -0.06627 0.029121 1086
rs585583-C -0.06187 0.303133 281
rs5919324-G 0.148322 1.96E-06 1022
rs61816764-T -0.0015 0.960888 1068
rs632205-T -0.07769 0.013291 1017 SIGNIFICANT SIGNIFICANT
rs6658216-C 0.073238 0.017945 1046 SIGNIFICANT
rs670741-T -0.0968 0.001637 1058
rs673449-C -0.05045 0.11521 978
rs67587000- no insertion 0.018299 0.552138 1060
rs692243-C -0.0723 0.024484 970
rs72696935-G -0.04852 0.112895 1071
rs72696940-A -0.00121 0.969134 1027 SIGNIFICANT SIGNIFICANT
rs73107581-T -0.0061 0.845641 1023
rs731236-G 0.030183 0.323721 1073
rs7349332-T 0.081653 0.007478 1074 SIGNIFICANT
rs741384-C 0.020888 0.498558 1054
rs74333950-G 0.056624 0.066767 1051
rs74868796-A -0.05581 0.074826 1022
rs75203436-G -0.06876 0.046591 840
rs756853-A -0.01481 0.629966 1062
rs75957773-C -0.02426 0.433657 1046
rs77157375-A 0.007138 0.81543 1074 SIGNIFICANT
rs78544048-C 2.61E-05 0.999346 991
rs80293268-C -0.11956 8.58E-05 1076
rs929626-G -0.01348 0.658456 1079
rs9535032-G 0.171171 3.78E-08 1022
rs9568036-A -0.17393 1.04E-08 1071 SIGNIFICANT SIGNIFICANT
rs9989836-A 0.082187 0.007285 1067
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Table 16 Pearson’s Correlation with Correction for Age and Sex 
 
Number Estimate p.value N, after removing NA Overall Mega analysis US pop-MEGA
rs10783518-C -0.07196 0.018298 1077
rs10788819-T -0.05064 0.098121 1070
rs10788826-T -0.02115 0.492296 1058
rs11150606-C -0.13352 1.19E-05 1071
rs11170678-G -0.04052 0.185773 1070
rs11203346-G -0.00098 0.974461 1080
rs11204897- G -0.06719 0.039868 938
rs11204925-G 0.012714 0.734852 714
rs1131471-T -0.07217 0.018065 1075
rs114410520-C -0.05841 0.057893 1057
rs11568820-T 0.176335 6.41E-08 930
rs11575161-T 0.010358 0.789914 666 SIGNIFICANT
rs11575194-A -0.04187 0.171484 1070
rs115813648-C -0.00154 0.959913 1064
rs11582331-T 0.023025 0.459111 1038
rs11585118-A -0.01744 0.58218 1000
rs11803731-T -0.1619 3.03E-07 992
rs12116760-T -0.05478 0.074485 1063
rs12123907-A -0.02596 0.394852 1078
rs12130862-T -0.10065 0.003518 841
rs12565727-G 0.094649 0.001828 1084
rs1268789-T 0.037382 0.219639 1082
rs12913832-G -0.16526 1.72E-06 831
rs12997742-C -0.10389 0.00085 1030
rs13015993-G 0.033714 0.268966 1079
rs140371183-G 0.034028 0.26542 1075 SIGNIFICANT
rs143290289-A -0.09478 0.002099 1053
rs144288709-A 0.027873 0.360358 1081
rs151069963-C -0.02824 0.357164 1067
rs1556547-A 0.031951 0.29527 1077
rs17646946-A -0.13181 2.12E-05 1036
rs17662023-A -0.0423 0.166593 1073
rs17730088-G -0.01493 0.628358 1055
rs1978346-A 0.002175 0.943356 1072
rs198607-C -0.02933 0.343145 1049
rs1998076-A -0.01781 0.58372 951
rs1999874-A 0.056195 0.069259 1048
rs2050631-G -0.09201 0.003426 1012
rs2146114-C 0.046945 0.12629 1064
rs2219783-G 0.157161 2.54E-07 1067 SIGNIFICANT SIGNIFICANT
rs2227311-G -0.02394 0.48561 853
rs2228570-A -0.05372 0.094816 970
rs2238136-T 0.002389 0.942632 912
rs2489250-T -0.05601 0.065789 1082 SIGNIFICANT
rs2784081-C -0.02849 0.352512 1069
rs3001978-T -0.0623 0.064266 885
rs3007671-T -0.01214 0.692493 1066
rs3007681-C -0.0357 0.249994 1042
rs310642-C 0.18404 5.94E-09 987
rs3827760-G -0.15983 1.47E-07 1072
rs436034-T -0.04142 0.177773 1062
rs4442975-G 0.10475 0.000632 1063
rs4480966-C -0.01233 0.687783 1066
rs4516035-C -0.09635 0.002382 994
rs4672907-A 0.190473 3.70E-10 1067
rs4674107-C -0.10147 0.000939 1062
rs4679955-T -0.0387 0.211476 1046
rs4845418-C -0.13944 2.17E-05 923
rs4845779-T 0.042728 0.170605 1032
rs499697-G -0.02964 0.333403 1069
rs505569-G 0.00497 0.870827 1075
rs551936-C -0.00755 0.804531 1078
rs55854644-T -0.0435 0.158362 1055
rs55883933-C -0.06627 0.029121 1086
rs585583-C -0.06187 0.303133 281
rs5919324-G 0.148322 1.96E-06 1022
rs61816764-T -0.0015 0.960888 1068
rs632205-T -0.07769 0.013291 1017 SIGNIFICANT SIGNIFICANT
rs6658216-C 0.073238 0.017945 1046 SIGNIFICANT
rs670741-T -0.0968 0.001637 1058
rs673449-C -0.05045 0.11521 978
rs67587000- no insertion 0.018299 0.552138 1060
rs692243-C -0.0723 0.024484 970
rs72696935-G -0.04852 0.112895 1071
rs72696940-A -0.00121 0.969134 1027 SIGNIFICANT SIGNIFICANT
rs73107581-T -0.0061 0.845641 1023
rs731236-G 0.030183 0.323721 1073
rs7349332-T 0.081653 0.007478 1074 SIGNIFICANT
rs741384-C 0.020888 0.498558 1054
rs74333950-G 0.056624 0.066767 1051
rs74868796-A -0.05581 0.074826 1022
rs75203436-G -0.06876 0.046591 840
rs756853-A -0.01481 0.629966 1062
rs75957773-C -0.02426 0.433657 1046
rs77157375-A 0.007138 0.81543 1074 SIGNIFICANT
rs78544048-C 2.61E-05 0.999346 991
rs80293268-C -0.11956 8.58E-05 1076
rs929626-G -0.01348 0.658456 1079
rs9535032-G 0.171171 3.78E-08 1022
rs9568036-A -0.17393 1.04E-08 1071 SIGNIFICANT SIGNIFICANT
rs9989836-A 0.082187 0.007285 1067
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APPENDIX R 
Table 17 Analysis of Optimization Run 
 
 
 
HIrisPlex-S SNP AVERAGE COVERAGE STANDARD DEVIATION
rs312262906 548 458
rs11547464 506 416
rs885479 506 416
rs1805008 506 416
rs1805005 453 361
rs1805006 456 361
rs1805007 506 415
rs1805009 12 9
rs201326893 506 415
rs2228479 453 361
rs1110400 506 415
Rs28777 146 125
Rs16891982 571 525
Rs12821256 57 140
Rs4959270 214 191
Rs12203592 23 15
Rs1042602 481 379
Rs1800407 124 93
Rs2402130 40 32
rs12913832 33 22
rs2378249 268 234
rs12896399 308 245
rs1393350 582 426
rs683 26 20
rs3114908 400 316
rs1800414 137 101
rs10756819 1254 942
rs2238289 46 34
rs17128291 91 73
rs6497292 248 204
rs1129038 183 130
rs1667394 182 139
rs1126809 203 144
rs1470608 70 49
rs1426654 12 10
rs6119471 35667 24878
rs1545397 4078 3083
rs6059655 419 333
rs12441727 294 237
rs3212355 137 102
rs8051733 1190 841
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APPENDIX S 
Table 18 Cost Analysis for 384 Samples on the Capillary Electrophoresis versus the 
Miseq 
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